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Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS), 
where myelin-reactive T cells play a key role in the inflammatory events responsible for 
the formation of demyelinated lesions. Auto-reactive T cells are present in the immune 
repertoire of healthy people, but they only rarely cause autoimmunity. Exact mechanisms 
by which autoreactive T cells become pathogenic are still unclear. 
In order to investigate these mechanisms, we used a transgenic Lewis rat model 
containing endogenous myelin basic protein (MBP)-reactive CD4 T cells and we analyzed 
these cells in naïve state or during experimental autoimmune encephalomyelitis (EAE) 
conditions. Further, we analyzed another experimental model, namely “memory” Lewis 
rats, which contain lifelong-persisting myelin-reactive memory CD4 T cells in their 
immune repertoire. Neither of these models develop spontaneous autoimmunity, 
however active immunization can readily induce disease with accelerated onset. We 
found that T cells of the memory but not of the naïve phenotype are capable of entering 
spinal cord tissue. Using intrathecal transfer of different T cells populations we were able 
to show that only freshly activated effector T cells are able to induce clinical disease after 
bypassing the blood brain barrier (BBB). After analysis of activation levels for different T 
cell subsets in active and transfer EAE, we hypothesized that the functional state of 
recently activated effector and not of resting memory MBP-specific T cells supports their 
pathogenicity and that such a state might be related to glycolytic activity. We studied 
glycolysis and factors regulating the metabolic switch after activation of MBP-specific T 
cells in vitro and after transfer in vivo during the course of transfer EAE. Of note, the 
inhibition of glycolysis by drug treatment in vivo delayed the onset of transfer EAE. This 
effect was associated with reduced inflammatory infiltration of the CNS tissue at the onset 
of disease. To confirm that the effect of in vivo glycolysis inhibition modulates the function 
of T cells, we tested a similar pharmacological approach in vitro and could show that 
inhibition of glycolysis in T cells prior to antigenic stimulation reduces the production of 
pro-inflammatory cytokines. 
Our results suggest that a high glycolytic rate enables CD4 T cells to perceive weak 
antigenic signals in the immune privileged tissue of the CNS and to become re-activated, 
triggering inflammatory processes. A therapy lowering the glycolytic rate in auto-
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1.1 T cell activation and self-tolerance  
The immune system is a network of cells communicating between each other by several 
mechanisms in order to protect the host organism from microbial pathogens. It can be 
divided into the innate and the adaptive immune system. Innate immunity represents the 
fast response system, comprising mainly phagocytic cells like macrophages, dendritic 
cells, and neutrophils as well as eosinophils, basophils, mast cells, cytotoxic cells like 
natural killer cells and the complement system. The cells belonging to the innate immune 
system recognize without fine specificity a broad range of pathogen-associated molecular 
patterns (PAMPs) by Toll-like receptors (TLR) and other pattern recognition receptors 
(PRRs) and initiate immune reactions. During the process of pathogen elimination the 
innate immune system tightly cooperates with the adaptive immune system. The latter 
consists mainly of lymphocytes, T cells and B cells which recognize pathogens by highly 
specific antigenic receptors (i.e. the T cell receptor (TCR) and B cell receptor, 
respectively) and carry out a delayed but much more precisely targeted response.  
T cells can be divided into CD4+ or helper T cells and CD8+ or cytotoxic T cells. They 
recognize the antigen presented by antigen presenting cells (APCs) such as phagocytes of 
the innate immune system via a set of proteins on their surface known as major 
histocompatibility complex (MHC), (this being MHC-II for CD4+ cells and MHC-I for CD8+ 
cells). The antigen presentation to the T cell receptor, together with costimulatory inputs, 
triggers complex signal-transduction pathways that lead to the activation and 
differentiation of the T cells (Knosp and Johnston 2012; Ramana et al. 2002; Shaw et al. 
1988). Both activation and differentiation can vary depending on several factors, 
including quality, duration and quantity of antigen presentation, ligand density, affinity, 
type of costimulatory signals and cytokine milieu. The activated state of T cells can be 
identified (and quantified) by proliferation and additionally by the production of 
inflammatory molecules such as the cytolytic enzymes granzyme B and perforin in CD8 T 
cells (Chávez-Galán et al. 2009). CD4 T helper cells produce cytokines (e.g. IFNγ, TNFα, 
IL-2, IL-17 or GM-CSF) and upregulate expression of the surface membrane receptors 
(e.g. CD69, CD25 orOX40) upon activation (Bikker et al. 2014; Codarri et al. 2011; Knosp 
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and Johnston 2012; Redmond, Ruby, and Weinberg 2009). By these and other molecules, 
CD4 T cells are able to fuel the activation of other immune cells and even of themselves. 
The tremendous variability of TCRs ensures that almost any pathogen can be targeted by 
adaptive immunity. However this wide range of specificities also implies that the T cell 
response can be directed against self-tissues which might ultimately result in the 
development of an autoimmune disease. The necessity of the immune system to 
discriminate between self and non-self gave rise to the development of self-tolerance 
mechanisms. In the case of T cells, the unresponsiveness to self can be obtained by central 
and peripheral mechanisms. The central tolerance is established during T cell 
development in the thymus where thymocytes expressing TCR with high affinity for self-
antigen/MHC complexes are deleted (negative selection). The highly self-reactive T cells 
that escape the negative selection can be inactivated in the periphery by mechanisms of 
peripheral tolerance that include deletion, suppression by regulatory cells and induction 
of an imprinted cell-intrinsic program mediating a state of functional unresponsiveness, 
or anergy (Schietinger and Greenberg 2014). 
The activation and differentiation of T cells are highly controlled and can change 
depending on the nature, context and duration of antigen presentation, potentially 
generating, as in the case of self-tolerance, various states of T-cell dysfunction and 
unresponsiveness. Anergy and ignorance, for example, are two described dysfunctional 
states. Anergic T cells are the result of sub-optimal stimulations like the absence of co-
stimulatory signals and are characterized by the inability to produce an effective immune 
response even in the presence of an optimal antigenic stimulus (Jenkins and Schwartz 
1987; Schietinger and Greenberg 2014; Schwartz 2003). Ignorance may occur when 
anatomical barriers sequester the (self-)antigen from immune surveillance or when the 
antigen is expressed or presented at too low concentrations to stimulate T cells. Hence, 
(self-)reactive T cells remain ignorant or unaware of the (self-)antigen. However, 
ignorant T cells are antigen-inexperienced and therefore persist as naïve but potentially 
functional cells. Thus, ignorance can be easily overcome (Kurts et al. 1999; Lang et al. 
2005; Oldstone et al. 1991; Schietinger and Greenberg 2014). 
The primary tasks of the immune system are the maintenance of tissue homeostasis and 
the defense of the organism against pathogens. The evolution towards a higher specificity 
of the immune response and hence the formation of the immunological memory has led 
on the one hand to a better performance of these tasks but on the other hand to the 
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possibility of harmful and counterproductive events. Indeed, under certain 
circumstances, the dysregulation of some immune mechanisms can cause self-tolerance 
to break down and the adaptive immune responses to be directed against self-tissue, 
inducing acute or chronic organ-directed autoimmune diseases such as type I diabetes, 
rheumatoid arthritis or multiple sclerosis (Dendrou, Fugger, and Friese 2015). 
 
1.2 The immunological memory 
A hallmark of the immune system is its potential to generate a secondary response to an 
infectious agent generally faster and more effectively than the primary response. This can 
occur because the recall responses are carried out by long-living, antigen-specific 
lymphocytes generated from the first exposure of a pathogen and able to readily and 
vigorously react to a new infection of the same agent. For this reason, these lymphocytes 
are called memory cells and represent experienced and specialized sentinels of the 
organism, putting the body under continuous immune surveillance in a quiescent and 
non-activated state, but ready to quickly respond in the case of an infiltration of the 
cognate pathogen. 
Currently there are two main models to explain the differentiation of T cells into memory 
cells, even if this concept is still debated (Restifo and Gattinoni 2013). The most known 
and accepted model (ON-OFF-ON / OFF-ON-OFF model) (FIG I) proposes naïve T cells to 
be stimulated by antigen, then proliferate and differentiate into effector cells producing 
cytokines and cytolytic molecules to clear the pathogen. After the peak of the response, 
once the antigen has been eliminated, most of the effector T cells enter the so-called 
contraction phase undergoing apoptosis, but a part of them survive and differentiate into 
memory cells that in turn can quickly become effector cells again and give rise to fast 
immune responses in occasion of a subsequent encounter with the cognate antigen. The 
second model (developmental model) (FIG I) opens up the possibility that effector T cells 
do not turn into memory cells but rather represent terminally differentiated cells. Hence, 
this model could involve asymmetric division of progenitor cells (Chang et al. 2007; 
Pollizzi et al. 2016) and the progressive differentiation of naïve T cells into memory and 









Memory T cells are predominantly quiescent but able to intermittently self-renew and 
survive long-term in the absence of cognate antigen (Pepper and Jenkins 2011), probably 
also owing to periodical activation through cross-reactive environmental antigens or self-
antigen (Sprent and Surh 2001). Memory T cells are heterogeneous, but the phenotype 
and function of the different subpopulations are still under discussion. In any case, among 
the CD4 memory T cells at least two classes have emerged, the central memory (Tcm) and 
the effector memory T cells (Tem). The latter express homing receptors that allow the 
migration to non-lymphoid organs, whereas Tcm, as well as naïve cells, express CD62L 
and CCR7, involved in the migration through the lymphoid sites (Sprent and Surh 2001). 
Moreover, both the subsets appear to respond well to antigen stimulation, with the Tem 
assuming the effector phenotype faster than the Tcm (Restifo and Gattinoni 2013; 
Sallusto, Geginat, and Lanzavecchia 2004). Finally, there is reason to believe that central 
memory T cells can differentiate from suboptimal antigen stimulations during the 
primary response (Langenkamp et al. 2000; Sallusto et al. 2004). 
 
1.3 Metabolism and T cell function: the role of glycolysis  
In order that naïve T cells can comply with the bioenergetic and biosynthetic demands 
occurring upon their activation due to rapid proliferation, differentiation and effector 
functions, these cells have to switch their metabolic program from a catabolic state 
relying mainly on fatty acid oxidation (FAO) and oxidative phosphorylation (OXPHOS) 
into an anabolic state. Indeed, the effector T-cell metabolism is based mostly on a superior 
uptake of nutrients such as amino acids, as suggested by evidence of increased 
glutaminolysis (Griffiths and Keast 1990), and mainly glucose. This sugar is then 
metabolized by aerobic glycolysis which represents the predominant metabolic pathway 
in effector cells (MacIver, Michalek, and Rathmell 2013), providing metabolic 
intermediates for de novo nucleotides and fatty acid synthesis and, however, to OXPHOS 
that is maintained engaged for a higher production of adenosine triphosphate (ATP)  
(Wang et al. 2011) (FIG II). In light of the above, T-cell activation and the metabolic 
reprogramming described above seem to be strictly correlated. One factor playing a 




target of rapamycin complex 1 (mTORC1) pathway, which integrates signals coming from 
TCR engagement, cytokine receptors, CD28 co-stimulation, amino acids and other 
nutrients with glycolysis up-regulation and metabolic reprogramming, nutrient uptake, 
biosynthesis, cell growth and cytokine production (Laky et al. 2015) (FIG II). 
During memory T cell development, T cells revert back to a catabolic state, down-
regulating aerobic glycolysis and using again mainly FAO and OXPHOS (FIG II). However, 
differently from naïve T cells, the memory T cells present an increased mitochondrial 
mass (Buck et al. 2016) and therefore a higher spare respiratory capacity (SRC) (Van der 
Windt et al. 2012) that could promote their long-term survival (Pearce et al. 2009) or 
even a rapid ATP production upon antigen encounter, favoring in this way the formation 
of a quick secondary response (Van der Windt et al. 2013). The metabolic switch in 
memory T cells seems to be dependent on memory T-cell-promoting cytokines like IL15 
and IL7 (Van der Windt et al. 2012) rather than on the absence of TCR signalling. An 
important role in this respect is also played by the function of the AMP-activated protein 
kinase (AMPK) which is able to inhibit the mTORC1 complex (FIG II) (Schackelford and 
Shaw 2009). Consistent with these findings are the observations that inhibiting glycolysis 
with 2-deoxy-D-glucose (2DG) (see below) and blocking mTORC1 with rapamycin 






FIG II Metabolic differences between effector and memory T cells (Man and Kallies 2015). 
 
During glycolysis, glucose is transformed into two molecules of pyruvate in a process 
which does not require oxygen and that generates two molecules of nicotinamide adenine 
dinucleotide (NADH) and two of ATP. Afterwards, pyruvate can be fully oxidized in the 
tricarboxylic acid (TCA) cycle. The TCA cycle generates NADH and reduces flavin adenine 
dinucleotide (FADH2) that can be used by the electron transport chain (ETC) to fuel 
OXPHOS (FIG III), a process dependent upon oxygen that produces 36 ATP molecules per 
glucose molecule. Alternatively, in absence of oxygen, pyruvate can be transformed into 
lactate through the activity of the enzyme lactate dehydrogenase A (LdhA), producing 
NAD+ for further use in glycolysis, thereby fueling this pathway (FIG III). From an 
energetic point of view, utilizing OXPHOS maximizes the quantity of ATP derived from 
glucose but, as described above, effector T cells engage aerobic glycolysis, characterized 
by the conversion of pyruvate into lactate despite the availability of oxygen for a complete 
oxidation via OXPHOS. This process, also called the Warburg effect, is a common feature 
of the actively proliferating cells (Pearce, Poffenberger, Chang, and Jones 2013). 
The fast processing of glucose induced by the Warburg effect (FIG III) allows the effector 




with many metabolic intermediates important for proliferation and cell growth. In fact, 
the metabolism of glucose through the pentose phosphate pathway (PPP) is important 
for nucleotide synthesis. Moreover, the pyruvate can enter the mitochondria as acetyl-
CoA, forming citrate in the first step of the TCA cycle, but then can be exported to the 
cytosol where is converted back to acetyl-CoA in order to start the free fatty acid 
synthesis (FAS). Interestingly, it was observed that inhibiting this pathway to FAS 
restrains the development of Th17 but favors the induction of regulatory T cells (Berod 
et al. 2014). Finally, the consequence of using glucose-derived citrate for lipid 
biosynthesis in the cytosol is the depletion of many metabolites from the TCA cycle. 
Therefore, in order to avoid mitochondrial dysfunction, the cells engage glutaminolysis 
that, inducing the formation of α-ketoglutarate (α-KG), is able to provide the 
mitochondria with the TCA cycle intermediates (Pearce, Poffenberger, Chang, and Jones 
2013) (FIG III).  
 
 





The metabolic programs associated with different T cell functions are regulated by 
signals coming from TCR engagement and cytokines. In the effector T cells, the signaling 
cascade of the PI3K-AKT1-mTORC1 pathway induces the expression of glycolysis-
associated transcription factors such as Myc (Myc proto-oncogene, bHLH transcription 
factor), hypoxia-inducible factor 1α (Hif1α) and interferon-regulatory factor 4 (Irf4) that 
positively regulate the transcription of glycolytic enzymes or molecules. At the same time, 
the mTORC1 pathway is responsible for the down-regulation of memory-cell-associated 
transcription factors like EOMES (eomesodermin) (Man and Kallies 2015) (FIG IV). Myc 
normally initiates cell division and is responsible for activation-associated glycolysis and 
glutaminolysis (Wang et al. 2011), Hif1α sustains glycolysis during T cell proliferation 
(Dang et al. 2011) and generally is up-regulated in low oxygen conditions; Irf4 was found 
to be able to stimulate the expression of Hif1α, sustain the glycolysis program and 
promote the expansion and differentiation of effector T cells and the maintenance of their 
effector functions (Man et al. 2013). It could also inhibit the expression of EOMES and, 
through the induction of BLIMP1, favors the down-regulation of another memory cell-
associated transcription factor as well as inhibitor of glycolysis, B cell lymphoma 6 (Bcl-






FIG IV Transcriptional regulation of metabolism in effector T cells. 
Cooperation between TCR - IL2 receptor signaling and metabolic transcription factors in the induction of 
the glycolytic program and effector T cell differentiation (adapted from Man and Kallies 2015). 
 
Recently the store-operated Ca2+ entry (SOCE) was emphasized to play a role in the 
regulation of aerobic glycolysis after TCR engagement, mainly through the action of the 
transcription factor NFAT (nuclear factor of activated T cells) on the expression of other 
transcription factors mentioned above (Vaeth et al. 2017). This regulation depends 
mainly on Ca2+ release-activated Ca2+ channels (CRAC) located in the plasma membrane. 
They represent the main source of intracellular of calcium influx upon TCR engagement 
and are critical for calcineurin activation. Upon TCR stimulation, the production of the 
second messenger inositol 1,4,5-trisphosphate (IP3) and the opening of IP3 receptor 
channels in the endoplasmic reticulum (ER) triggers the release of Ca2+ into the cytosol. 
The subsequent decrease in the Ca2+ concentration in the ER results in the dissociation of 
Ca2+ from stromal interaction molecules (STIMs) located in the ER membrane. In this way, 




influx called store-operated Ca2+ entry because it is regulated by the Ca2+ concentration 
inside the ER. Afterward, calcineurin is activated by the free cytosolic Ca2+ and in turn 
induces the nuclear translocation and transcriptional activity of NFAT (Vaeth et al. 2017). 
Importantly, the metabolic activity can directly regulate the expression of effector 
molecules. In fact, high glycolytic flux maximizes cytokine production by recruiting 
glycolytic enzymes such as GAPDH and LdhA that, in conditions of low glycolysis rate, 
bind regions of mRNA, inhibiting the translation of inflammatory cytokines (Chang et al. 
2013; Menk et al. 2018). Moreover, the higher presence of glycolytic metabolites such as 
phosphoenolpyruvate (PEP) favors the inhibition of sarco/endoplasmic reticulum Ca2+-
ATPase (SERCA), responsible of the Ca2+ uptake into the ER. It results in an increase of 
Ca2+ cytosolic concentration that promotes NFAT nuclear translocation and thereby, 
elevated cytokine production and tumoricidal activities of T cells (Ho et al. 2015).  
In conclusion, there is some evidence for glycolysis being correlated with the T cell 
functional state, and for a manipulation of glycolysis during antigen stimulation affecting 
the differentiation, activation and performance of T-cell effector functions. It was also 
observed that the nutritional milieu, for instance a low or high glucose concentration in 
the extracellular space of the area where T cells encounter the antigen, can influence the 
T cell activation as a result of changes in the glycolysis rate (Ho et al. 2015).  
However, it is still not clear if the cellular level of glycolysis prior to stimulation is able to 
influence the level of activation of T cells once they encounter the antigen, even in optimal 
environmental conditions. In other words, we still do not know if the level of glycolysis 
in T cells in homeostatic conditions can influence the immune potential of these cells. 
 
1.4 Multiple sclerosis, an autoimmune disease 
Multiple sclerosis (MS) is a chronic neuroinflammatory demyelinating disease of the 
central nervous system (CNS). It is a common cause of physical disability in young adults, 
especially women (Compston and Coles 2008). The average age of disease onset is 30 
years and 25 years after diagnosis, approximately 50% of patients require permanent use 
of a wheelchair. The symptoms have a very heterogeneous presentation, including 
sensory and visual disturbances, motor impairments, fatigue, pain and cognitive deficits 




spatiotemporal dissemination of the lesions within the CNS (Kearney et al. 2015). These 
lesions are a hallmark of MS and are caused by immune cell infiltration across the blood-
brain barrier (BBB) that promotes inflammation, demyelination, gliosis and neuroaxonal 
degeneration, leading to disruption of neuronal signalling (Frischer et al. 2009). T cells 
appear early in lesion formation, therefore MS is classed as an autoimmune disease, 
initiated by autoreactive lymphocytes mounting aberrant responses against CNS 
autoantigens, the precise nature of which is still unclear. Three most common forms of 
disease progression have been defined: relapsing-remitting MS (RR-MS), secondary 
progressive MS (SP-MS) and primary progressive disease (PP-MS). RR-MS affects 85 % of 
patients and is characterized by recurring bouts of relapse and remission where relapses 
coincide with focal CNS inflammation and demyelination. Later, about 80% of these 
patients develop SP-MS. During this stage, inflammatory lesions are no longer 
characteristic, and the progressive neurological decline is accompanied by CNS atrophy. 
Finally, approximately 10% of patients are diagnosed with PP-MS, which shows a 
progressive decline from the outset in absence of relapses (Dendrou, Fugger, and Friese 
2015). 
The etiology of MS is poorly understood. Several factors have been proposed to 
contribute to MS pathogenesis including genetic and environmental risk factors. Genetic 
variation accounts for approximately 30% of the overall disease risk, and genome-wide 
association studies identified more than 100 distinct genetic regions associated with 
multiple sclerosis (Beecham et al. 2013) the majority of which is thought to be 
immunological, i.e. HLA variants essential for antigen presentation and genes encoding 
molecules involved in T cell biology such as IL-2Rα, IL-7Rα and CD6 (Gourraud et al. 
2012). The environmental factors can possibly trigger the autoreactivity or modulate the 
activation of the auto-reactive immune cells (Dendrou, Fugger, and Friese 2015). Among 
them, viral factors like Epstein-Barr virus (Ascherio and Munger 2007; Serafini et al. 
2010) and cytomegalovirus, or factors linked to the lifestyle, such as smoking, vitamin D 
(Belbasis et al. 2015), diet (Yatsunenko et al. 2012) and circadian disruption (Hedström 
et al. 2011) could contribute to MS by several mechanisms, including the induction of 
peripheral activation of CNS-reactive T cells by molecular mimicry and bystander 
activation, thus facilitating their infiltration into the CNS. Furthermore, the CNS-reactive 
T cells could be activated directly in the inflamed CNS by epitope spreading (Harkiolaki 




Besides the immunological genetic association with multiple sclerosis, the autoimmune 
nature of the disease is strongly supported by the evidence of the infiltration of immune 
cells, including T lymphocytes, B lymphocytes and macrophages within CNS lesions 
(Lucchinetti et al. 2000; Serafini et al. 2004) of patients with different MS stages. 
It has not been possible to identify a single CNS-protein as a universal target for the 
autoimmune response in MS. CD4+ T cells reactive to myelin-derived self-antigens such 
as myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG) and 
proteolipid protein (PLP) were found in the immune repertoires of both healthy 
individuals and MS patients (Hohlfeld, Dornmair, Meinl, and Wekerle 2016; Hellings et al. 
2001). For those specificities, an increased frequency and activation of T cells was 
reported in MS patients (Ota et al. 1990; Pette et al. 1990; Bielekova et al. 2004; Tejada-
Simon et al. 2001). Aquaporin-4 (AQP4) has been identified as candidate antigen causing 
B cell responses and production of autoantibodies in neuromyelitis optica (NMO), an 
inflammatory and demyelinating disease affecting mainly the optic nerve but also the 
spinal cord (Lennon et al. 2005; Lennon et al. 2004). Interestingly, in NMO lesions a 
profound loss of AQP4+ astrocytes could be observed (Brück et al. 2012). An autoantibody 
response to the potassium channel KIR4.1 was also found in MS patients (Srivastava et 
al. 2012). 
Finally, another convincing piece of evidence about the role played by T and other 
immune cells in the pathogenesis of MS is that therapies demonstrating efficacy in MS 
patients target mainly, or even exclusively, the immune system. Among these treatments, 
Alemtuzumab, for example, depletes lymphocytes, Teriflunomide inhibits their 
proliferation, IFNβ modulates lymphocyte activation and differentiation, Rituximab 
depletes the B cells and Natalizumab interferes with lymphocyte migration into the CNS. 
 
1.5 The CNS, an immune privileged organ 
The CNS is considered to be an immune-privileged site, i.e. an area in the body with a 
decreased immune response to foreign antigens, including tissue grafts (Dendrou, 
Fugger, and Friese 2015). Thus, the threshold for immune activation in the CNS is higher 
than in the periphery. This special “privileged” state evolved to provide a balance 




possibility of an irreversible and fatal immune-mediated damage to this tissue. Indeed, 
the presence of post-mitotic neural cells not able to self-renew but controlling many vital 
physiologic functions must coexist with mechanisms that reduce dangerous 
inflammatory reactions threatening the life of the whole organism. 
The immune-privileged status of the CNS has been attributed to the parenchymal anti-
inflammatory milieu, the lack of constitutive MHC class I and II expression, the lower 
efficiency of CNS-resident APCs in eliciting T cell immune responses (Wlodarczyk et al. 
2014; Flügel et al. 1999b) and the presence of periendothelial barriers that prevent the 
free diffusion of molecules and restrict the leucocyte trafficking in the tissue, including 
the BBB, the blood-cerebrospinal fluid (CSF) and the blood-leptomeningeal barriers. 
(Dendrou, Fugger, and Friese 2015; Engelhardt and Ransohoff 2005).  
However, even in a healthy CNS, T cells traffic in perivascular, subarachnoid or meningeal 
spaces, indicating their capacity to take constitutively the CNS under immune-
surveillance without disrupting the BBB (Shechter, London, and Schwartz 2013). 
Consistent with this, blood-derived antigen-presenting cells constitutively expressing 
MHC class II are localized in the meningeal, ventricular and perivascular spaces in order 
to present the antigen to the patrolling T cells, whereas microglial cells fulfill this function 
in the parenchyma and, as observed in MS animal models, can activate CNS-reactive T 
cells in high inflammatory conditions (McMahon et al. 2005; Lodygin et al. 2013).  
Although there is much information about genetic and environmental factors involved in 
MS pathogenesis and speculation about their role in triggering the onset of the disease, 
the mechanisms, the circumstances and the elements crucial in the dysregulation of the 
central and peripheral tolerance and in the stimulation of immune cells to inducing and 
then maintaining inflammatory events against auto-antigens in the CNS are still to be 
elucidated. What triggers APCs to start presenting CNS-derived antigens or how a 
physiological immune-surveillance can turn into an auto-disruptive situation are still 
unanswered questions. Furthermore, the mechanisms which allow the immune cells to 
become able to pass through the BBB and induce the pathological autoinflammatory 
response inside the CNS, i.e. overcoming the high pathogenicity threshold of such 
immune-privileged organ, are still unclear but could represent potential targets for 
further therapies.  
A possible way to elucidate at least some of these mechanisms and create new concepts 




1.6 Experimental autoimmune encephalomyelitis (EAE) 
The limited amount of biological samples derived from MS patients and the impossibility 
to study the entire course of the disease already starting from the preclinical phase, 
together with the high heterogeneity of MS, are all factors complicating the study of this 
disease, in particular, its mechanistic aspects. For this reason, the creation of animal 
models that can mimic at least some of the pathological events and the symptoms of MS 
is indispensable. 
The first evidence that an immune reaction against CNS components leads to brain 
inflammation was reported by Rivers in 1928 when he described an epidemics of 
paralysis among people vaccinated for rabies (Remlinger 1928; Baxter 2007). Afterward, 
it was observed that immunization with CNS tissue led to the formation of demyelinating 
lesions in monkeys (Rivers 1935; Schwentker and Rivers 1934). These findings, together 
with the establishment of an emulsion called complete Freund’s adjuvant (CFA) 
containing lyophilized mycobacterium tuberculosis and paraffin oil, able to facilitate 
immune responses in host animals, favored the development of CNS inflammation model 
caused by autoimmune reactions. This animal model was called experimental 
autoimmune encephalomyelitis (EAE) (Freund and McDermott 1942) and was based on 
the generation of a peripheral immune reaction against a self-CNS-antigens favoring the 
formation of auto-reactive activated immune cells able to migrate to the CNS and lead 
demyelinating inflammatory events. Nowadays EAE represents the classical animal 
model with which to study autoimmune processes in the CNS. One of the main modalities 
to induce EAE is named active EAE (aEAE), characterized by the immunization of the 
experimental animal with myelin proteins in combination with CFA. Active EAE can be 
induced in several species including primates (Rivers et al. 1933), dogs (Thomas et al. 
1950), mice (Olitsky and Yager, 1949) and rats (Lipton and Freund, 1952) Moreover, 
several antigens can be used for the induction of active EAE. Widely used antigens are 
myelin components such as MBP, MOG, myelin-associated glycoprotein (MAG) and PLP, 
but also non-myelin antigens like S-100β expressed primarily in astrocytes and the 
medium-sized neurofilament (NF-M) for instance (Linington et al. 1988; Piddlesden et al. 
1993; Kojima et al. 1994; Kaye et al. 2000). 
The genetic background of species and strains, or the nature of antigen can determine the 




models are the chronic paralytic disease induced by MOG35-55 immunization in the 
C57BL/6 strain (Mendel et al. 1995) and the PLP139-151-induced relapsing-remitting EAE 
in the SJL/J strain (Tuohy et al. 1988), whereas the MBP immunization in Lewis rats 
generates a monophasic EAE course (Lipton and Freund 1953). 
An alternative way to induce EAE consists of transferring myelin-specific T cells into 
healthy animals (Bell and Paterson 1960), and is called adoptive or passive, or transfer 
EAE (tEAE). This tEAE model was developed in Lewis rats, where lymphocytes from MBP-
immunized animals cultured under CD4+ T cell-favoring conditions and subsequently 
transferred into syngeneic animals were able to induce a classical EAE course after a 
defined period of time (Ben-Nun et al. 1981). Today, both Th1 CD4 T cells producing IFNγ 
and Th17 CD4 T cells producing IL-17 are recognized to be important for the EAE 
induction (Baron et al. 1993; Segal and Shevac 1996; Cua et al. 2003; Zepp, Wu, and Li 
2011). 
 
1.7 Active EAE in Lewis rats 
In Lewis rats, active EAE comes in the form of an acute paralytic disease. It is induced via 
subcutaneous immunization of naïve rats with guinea pig MBP (or MBP peptide 
corresponding to aminoacids 68-88) emulsified in CFA. Circa ten days after 
immunization, Lewis rats develop clinical EAE characterized by loss of body weight as 
first appearing symptom, followed by paresis of the tail that then ascend to a complete 
paralysis of the hind limbs and in some cases to a partial paralysis of the front limbs at 
the peak of the disease. The active EAE course is monophasic so the Lewis rats recover 
completely a few days after reaching the EAE peak. In total, the whole EAE phase, from 
the onset to the complete recovery, lasts 8 – 9 days. The development of clinical 
symptoms is accompanied by CNS infiltration by T cells, phagocytes and other immune 
cells (Huitinga et al. 1995), primarily detected in the spinal cord. Lewis rats challenged 





1.8 Transfer EAE in Lewis rats 
The tEAE in Lewis rats is commonly induced by injection of MBP-specific CD4+ effector 
T cells activated in vitro (FIG V) (Ben-Nun et al. 1981; Wekerle et al. 2008). The onset of 
disease occurs usually about 3 days (FIG V) after T cell transfer and the clinical signs and 
disease course resembles that of aEAE. To evoke inflammation and the development of 
the pathology, the transferred T cells transmigrate the BBB and become reactivated 
within the CNS, causing an inflammatory milieu and a dysfunction of the BBB (Flügel et 
al. 2001; Kawakami et al. 2004). These events favor the recruitment of other immune cells 
including lymphocytes and myeloid cells that together with the ones already inside the 
tissue contribute to creating an inflammatory environment and thus to demyelination 
and CNS damage.  
One advantage of using the transfer of myelin-specific T cells to evoke EAE is the 
possibility to genetically engineer these T cells to express fluorescent markers or other 
genes (Flügel et al. 1999). Using green fluorescent protein (GFP)-tagged MBP-specific T 
cell lines generated ex vivo, for instance, it is possible to identify them in vivo during all 
the phases of tEAE and analyze their behavior, their function and phenotype by 
combining in vivo imaging and ex vivo characterization (Kawakami et al. 2005b; 
Bartholomäus et al. 2009; Schläger et al. 2016). 
Notably, the clinical signs of tEAE do not occur immediately after T cell transfer but rather 
only after a prodromal phase of about 3 days (Wekerle et al. 1994). Owing to the use of 
engineered fluorescent MBP-specific T cells in tEAE experiments, it was found that soon 
after transfer the T cells disappear from the circulation and home directly into the lung 
for about one day. Afterward, they move to the lung-draining mediastinal lymph nodes 
(med LNs) and subsequently, sometime between the second and the third day after 
transfer, re-enter the circulation, move to the spleen and then invade the CNS, mainly the 
spinal cord (SC) (FIG V) (Odoardi et al. 2012). 
It is noteworthy that already in the lung the T cells switch on their migratory program, 
upregulating adhesion molecules such as LFA-1 and VLA-4 and chemokine receptors 
including CXCR3, CXCR4 and S1P1. However, on the other hand, they downregulate their 
activation factors such as IFNγ, TNFα and CD25. This reprogramming seems to facilitate 
the migration of these cells through the BBB and so their access into the SC where they 




the T cells get reactivated and produce inflammatory cytokines (IFNγ, IL-17, GM-CSF) and 
membranous activation markers (CD25 and OX40) (Lodygin et al. 2013; Odoardi et al. 
2012), thus setting up the precondition for the recruitment of other immune cells, the 
local cascade of inflammatory events and the onset of EAE. 
Figure V presents a schematic view of different stages through which MBP-specific T cells 
proceed before they enter the spinal cord and induce disease. MBP-specific T cells are 
stimulated with thymocytes as APCs and MBP, in the course of which they switch on an 
activatory transcriptional response, then cluster and start to proliferate. On the day 2, 
when the activatory transcription is completed, they reach the maximal activatory and 
effector phase that represents the suitable moment for these cells to be intravenously 
transferred into the animals to ensure induction of EAE. The non-transferred cells keep 
proliferating massively until the 3rd day and a bit beyond, and then start to reduce 
proliferation and slowly become resting over time until the next re-stimulation, normally 
on day 6 or 7. 
After transfer in vivo, the T cells follow the pathway described above and, based on this, 
FIG V indicates in which organ and on what day it is possible to find the cells in order to 
analyze them. Finally, on day 3 after transfer, the T cells enter the SC, get reactivated and 






FIG V Life cycle of effector cell line used for transfer EAE in Lewis rats. 
Schematic view of a time course of changes that MBP-specific T cells undergo in vitro and in vivo before 
induction of transfer EAE. SC, spinal cord; medLNs, mediastinal lymph nodes. 
 
1.9 Generation of TCR transgenic Lewis rats 
Active and transfer EAE in wild-type (WT) Lewis rats are very useful and reliable MS 
animal models. However, they rely on immune reactions induced by external inputs like 
MBP immunization with the use of adjuvant and the injection of MBP-specific CD4+ 
effector T cells activated in vitro, leaving all the endogenous MBP-specific T cells and their 
functions unavailable for analysis. The generation of transgenic rats in which the majority 
of T cells express a TCR specific for MBP provides the possibility of studying these auto-
reactive T cells in their natural environment, to characterize their phenotype and to 
analyze their activation and functionality either in the homeostatic condition or during 
induction of EAE. Furthermore, as observed in different TCR-transgenic mouse strains 




animals may develop a spontaneous disease can facilitate the unveiling of factors and 
mechanisms underlying or influencing the capacity of autoreactive T cells to differentiate 
into pathogenic subsets and induce EAE.  
In our laboratory two novel TCR transgenic rat strains on Lewis genetic background were 
generated. One of these, known as rMT-II, standing for rat MBP-specific T cell receptor 
MHC class II-restricted, harbors TCR recognizing the myelin autoantigen MBP. 
To obtain the DNA sequence for the reconstruction of the T cell receptor specific for MBP, 
the clonal T cell line Z85 where a variable segment of the β chain is known to be Vβ8.2 
was used (Chluba et al. 1989). After identification of a matching alpha-chain sequence, a 
lentiviral construct was generated as shown in (FIG VIA). 
The generation of rMT-II rats was achieved by injecting the concentrated lentiviral 
particles into the perivitelline space of fertilized oocytes. (FIG VIB). The founder animals 
positive for integration were identified, crossed to WT Lewis to check for germ line 
transmission and the F1 generation was inter-crossed). This yielded progenies with no, 
medium or high GFP expression in frequencies fitting to Mendelian laws. Breeding of rats 
with high GFP expression resulted in animals which were uniformly “high-GFP” 
suggesting that those rats were homozygous for the rMT-II allele (designated Tg/Tg or 















FIG VI Generation of TCR transgenic rMT-II rats (Lodygin, Kitz et al. unpublished). 
(A) Schematic view of the lentiviral (LV) expression construct encoding fluorescent marker (GFP) and rat 
TCR specific for myelin basic protein. (B) Procedure for the formation of rMT-II rats. (C) GFP expression in 




In the secondary lymphoid organs and in the blood of homozygous transgenic rats (rMT-
II+/+), the CD8+ T cell population was reduced and the vast majority of T cells were CD4+. 
Moreover, in rMT-II rats were observed naïve and memory CD4 T cell populations, 
distinguished by the expression of CD62L (L-selectin), being expressed in naïve and 
down-regulated in memory cells. In fact, although in mice naïve T cells are defined as a 
CD62Lhigh CD44low (Sallusto et al. 1999), in rats CD44 is highly expressed in both naïve 
and effector/memory T cells and cannot be used to discriminate them. Instead, it was 
observed that both CD62L and CD45RC are expressed in naïve rat T cells and become 
down-regulated upon differentiation into effector or memory T cells (Bunce and Bell 
1997). In contrast, there is some evidence showing that CD62L is expressed in naïve and 
in central memory T cells, but not in the effector memory ones (Sprent and Surh 2001). 
In summary, it is possible to conclude that the CD62L+ population could be composed of 
one portion of naïve cells and another of central memory cells, whereas the CD62L- 
population is composed only of memory T cells.  
Along with rMT-II rats, a control transgenic Lewis rat with a TCR specific for the non-self-
antigen chicken egg ovalbumin (OVA) was generated using similar strategy. This strain 
was designated as rOT-II, standing for rat OVA-specific TCR transgenic MHC class II 
restricted. In the OVA-specific TCR, the variable region of the β chain is Vβ16 (FIG VIIA).  
T cells derived from rMT-II+/+ and rOT-II+/+ (homozygous) but not from WT rats 
proliferated in response to the respective specific antigen in a dose-dependent manner 
but did not do so upon stimulation with the non-specific protein. Only a minimal 
proliferative response was present in hemizygous T cells (bearing a single TCR transgenic 
allele) at the maximum concentration of antigen. It is noteworthy that T cell proliferation 
was abolished in cultures pretreated with OX-6 antibody blocking the rat MHCII complex 
(FIG VIIB). 
Interestingly, only 50 % of the rOT-II+/- and 12.5 % of the rOT-II+/+ rats developed EAE 
after immunization with MBP in CFA. Therefore, even if most of the T cells in rOT-II rats 
expressed the OVA-specific TCR, the residual non-transgenic repertoire still retained the 
capacity to induce EAE by MBP-immunization. However, this observation makes rOT-II 





FIG VII T cell specificity in rMT-II and rOT-II rats (Lodygin, Kitz et al. unpublished). 
(A) Expression of Vβ-chains in peripheral blood T cells of WT and rMT-II+/+ and rOT-II+/+ rats. Flow 
cytometry data (gated on αβTCR+ population). 
(B) Proliferation ([3H]-thymidine incorporation assay; c.p.m., counts per minute) of WT, rMT-II+/+, rMT-II+/-, 
rOT-II+/+, rOT-II+/- lymph node T cells measured 48 h after indicated stimulations. 
 
1.10 Generation of “memory” Lewis rats 
In order to study the function of MBP-specific memory CD4 T cells in Lewis rats, 
Kawakami et al. generated so called “memory rats” characterized by the lifelong 
persistence of encephalitogenic T cell clones in healthy immune repertoires (Kawakami 
et al. 2005). To this end, effector CD4 T cells specific for MBP retrovirally engineered to 
express GFP were injected intraperitoneally (i.p.) into newborn syngeneic Lewis pups. 
The T cell lines were i.p. transferred 4 – 5 days after antigen restimulation in vitro. 
Interestingly, these cells persisted lifelong in the host animals, even if in low numbers. 
They were found in all the lymphoid organs, in the blood and also in other non-immune 
organs and, noteworthy, maintained a memory phenotype with low levels of CD62L and 




did not provoke any spontaneous clinical signs. However, “memory” rats exhibited an 
earlier onset of MBP/CFA-induced aEAE compared to the WT counterparts (FIG VIIIA), 
confirming the functionality of the memory T cells. Furthermore, “memory” rats showed 
a pathogenic reaction against an immunization with MBP/IFA (incomplete Freund’s 
adjuvant), a regimen that failed to induce EAE in WT animals (FIG VIIIB) (Kawakami et 
al. 2005).  
 
FIG VIII Active EAE induction in “memory” rats.  
(A) EAE induction by MBP/CFA. (B) EAE induction by MBP/IFA. (A,B) Clinical score (left y-axis, bars) and 
weight changes (right y-axis, curves) of memory animals (black) and age-matched non-memory control 







MBP-reactive T cells were detected in the blood of healthy humans yet had not caused 
autoimmune disease (Hohlfeld, Dornmair, Meinl, and Wekerle 2016). Presumably, these 
auto-reactive T cells need particular circumstances and the manifestation of extrinsic 
and/or intrinsic factors in order to trigger their activation and pathogenicity and 
contribute to the onset of autoimmune diseases. In order to investigate the factors and 
the mechanisms underpinning the activation of latent MBP-reactive T cells, we decided 
to exploit the properties of TCR transgenic rMT-II and “memory” Lewis rats. Interestingly, 
as previously indicated (Kavakami et al. 2005), EAE does not occur spontaneously in 
either of these two models, even though these animals are highly susceptible to EAE 
induced by active immunization. As shown in FIG 1, rMT-II rats did not show any further 
aggravation of the transfer EAE compared to WT rats. These findings prompted us to 
analyze in details the phenotype and encephalitogenic properties of T cells in different 
compartments and at different time points in rMT-II TCR transgenic and TMBP-memory 
animals subjected to active or passive induction of neuroinflammatory disease. 
Furthermore, we decided to focus on the metabolic pathways, mainly on the glycolysis, 
which had been previously shown to distinguish various subsets of T cells (naïve versus 
effector, effector versus memory etc.) and to be important for modulating their functions. 
One of the central questions of the project was whether the glycolytic rate set by the 
preceding antigenic stimulation in the periphery (or in vitro) may directly affect the 
potential of T cells to become re-activated inside the CNS and thus contribute to the 





3. MATERIALS AND METHODS 
3.1 Buffers 
Table 1 Basic buffers and composition. 




10X Phosphate buffered saline (PBS) 
80 mM Na2HPO4 
1.5 M NaCl 
20 mM KH2PO4 
30 mM KCl 
pH 7.4 
1X PBS 10 x PBS diluted ten times in distilled water 
ACK (Ammonium chloride 
potassium) buffer 
0.15 M NH4Cl 
10 mM KHCO3 
0.1 mM Ethylenediaminetetraacetic acid 
(EDTA) 
Fluorescence-activated cell sorting 
(FACS) buffer 
0.5 % Bovine serum albumin (BSA) 
0.05 % Natrium acide 
in PBS 
Magnetic-activated cell sorting 
(MACS) buffer 
2mM EDTA 
2% Fetal calf serum (FCS) (Biochrom AG, 
Berlin, Germany)) 
in 1X PBS 
Washing buffer (for ELISA) 0,05% Tween-20 in 1X PBS 
Blocking buffer (for ELISA) 10% FCS in 1X PBS 
Isotonic Percoll 
90% Percoll (GE Healthcare) 




3.2 Primary T cell culture 
3.2.1 Media composition 
Media Composition 
Dulbecco’s Modified Eagle’s 
medium (DMEM) 
Gibco DMEM Powder (Invitrogen, Carlsbad, USA) 
1.2 g/l NaHCO3 (Carl Roth, Karlsruhe, Germany) 
Eagle’s HEPES medium (EH) 
DMEM 
25 mM Gibco Hepes (Invitrogen, Carlsbad, USA) 
T cell medium (TCM) 
DMEM 
1 % Gibco non-essential amino acids (Invitrogen, Carlsbad, USA) 
1 % Gibco sodium pyruvate (Invitrogen, Carlsbad, USA) 
1 % Gibco Penicillin/Streptomycin (Invitrogen, Carlsbad, USA) 
1 % L-glutamine (Pan Biotech GmbH, Aidenbach, Germany) 
1 % Asparagine Monohydrate (Sigma Aldrich, Munich, Germany) 
4 µl/L β-mercaptoethanol (stock 13,6M, Invitrogen, Carlsbad, 
USA) 
Restimulation medium (RM) 
TCM 
1% rat serum 
T cell growth factor (TCGF) 
TCM 
10 % horse serum (Biochom Ag, Berlin, Germany) 
5 % Conditioned medium from mouse splenocytes treated with 
the mitogen concanavalin A (Rosenberg et al. 1978) (Sigma 
Aldrich, Munich, Germany) 
Freezing medium 
TCM  
50 - 80 % horse serum (Biochom Ag, Berlin, Germany) 
10% DMSO (Carl Roth GmbH, Karlsruhe, Germany) 
Glucose-free DMEM Gibco DMEM deprived of glucose (Life technologies)  
Galactose + 2 Deoxy-D-glucose (2-
DG) TCM 
Glucose-free DMEM 
1 % Gibco non-essential amino acids  
1 % Gibco sodium pyruvate  
1 % Gibco Penicillin/Streptomycin  
1 % L-glutamine  
1 % Asparagine Monohydrate  
4 µl/L β-mercaptoethanol  
22,7mM D-(+)-Galactose (Sigma Aldrich, Munich, Germany). The 
concentration is equivalent to that of glucose in DMEM. 
5mM 2-DG (Carbosynth, Compston, Berkshire, UK)  
Galactose + 2-DG RM 
Galactose + 2-DG TCM 
1% rat serum 
Galactose + 2-DG TCGF 
Galactose + 2-DG TCM 
10 % horse serum (Biochom Ag, Berlin, Germany) 
5 % Conditioned medium from mouse splenocytes treated with 
the mitogen concanavalin A (Sigma Aldrich, Munich, Germany) 




3.2.2 Culture of packaging cells 
GP+E86 (mouse fibroblasts) packaging cells, producing a replication-deficient GFP or 
mCherry (red fluorescent protein) fluorescent protein retrovirus, were used to transduce 
T cells. The retroviral vector for the gene transfer promotes the transfer of a resistance 
to the neomycin derivative G418 (Invitrogen) or puromycin (Roth) (Flügel et al. 1999) 
All the processes described here and during all the primary T cell culture generation 
procedure were performed under a laminar flow (Laminar Flow Hera Safe, from Heraeus). 
Before co-culturing with primary T cells, packaging cells were cultured in TCM + 10% FCS 
and G418 (0,4 mg/ml) or puromycin (2 μg/ml) depending on the resistance of the cells 
in T75 flasks (Sarstedt). They were kept under 5 % CO2 humidified atmosphere in an 
incubator (Thermo Scientific) at 37 °C.  
Upon reaching a confluence of about 80 % the packaging cell lines were split. To that end, 
the cells were washed with 1X PBS and then incubated for 1 - 2 minutes with the 
endopeptidase trypsin (PAA) diluted 1:10 with PBS (from a 10X stock solution). 
The digestion process by trypsin was stopped by TCM + 10% FCS. Afterwards, the cells 
were centrifuged for 6 min with 1200 rpm at 4°C to remove trypsin residues. After 
centrifugation, the supernatant was discarded and the pellet resolved in TCM + 10 % FCS 
and 2 μg/ml puromycin or 0.1 mg/ml G418, depending on the cell line. Before co-culture 
with primary T cells, the packaging cells were cultured for about 2 days without any 
specific selection agent. 
3.2.3 Primary T cell cultures 
The process used to generate MBP-reactive CD4+ T cells retrovirally engineered to 
express fluorescent proteins (GFP or mCherry) is reported in the literature (Flügel et al. 
1999).  
As a first step, naïve female Lewis rats (8 to 10 weeks old) were immunized with MBP in 
CFA (see below). MBP was isolated from the brain of guinea pig as already described 
(Eylar et al. 1974).  
Cells were harvested from the draining lymph nodes (LNs) of immunized animals 
(popliteal, inguinal and para-aortal LNs) on day 10 after immunization, corresponding to 




Briefly, the LNs were minced and separated through a metal mesh in EH medium. The cell 
suspension was spun down (1200 rpm, 8 min, 4°C) and the cell pellet was washed with 
EH medium.  
On the same day, packaging cells were seeded into round-bottom 96-well plates (Nunc, 
Thermo Fischer Scientific Inc., Waltham, US) at a concentration of 15,000 cells/well in 
100 µl RM. 
The LN cells were added to the 96-well plates containing GPE at a concentration of 
200.000 cells/well, with the addition of 8 µg/ml MBP. Two days afterwards, 50 µl of TCGF 
medium were added to the cells and, if necessary, supplemented with antibiotics for cell 
selection. 
On day 3 or 4, 50 μl of medium per well were removed and the cells were moved into flat 
bottom 96-well plates (Nunc, Thermo Fischer Scientific Inc., Waltham, US). Afterwards, 
100 μl of fresh TCGF containing G418 (0.4 mg/ml) or puromycin (1μg/ml) were added 
into each well.  
On day 7, the first stimulation of T cells was performed: As a first step, 100 μl of medium 
per well were removed and subsequently 1.4 x 106 irradiated syngeneic thymocytes (30 
Gy irradiation), used as antigen presenting cells, were added into each well, diluted in 
100 μl RM in the presence of 8 μg/ml MBP. 
Two days after re-stimulation, TCGF (50 μl) was added into each well together with 
antibiotics in order to support selection and T cell proliferation.  
On day 3 after re-stimulation, the wells with the best viral transduced T cells (measured 
by fluorescence intensity and the best growth capacity) were chosen and pooled into 60 
mm Petri dishes (Sarstedt) where they were kept until the next re-stimulation on day 7. 
To be restimulated, 3.5 x 106 T cells were mixed with 70 x 106 irradiated syngeneic 
thymocytes and 8 µg/ml antigen in 5 ml RM per 60 mm Petri dish. On day 2, TCGF medium 
(about 2 ml per dish) was supplied to support the proliferation of the cells.  
In order to maintain an optimal density, T cells were transferred into 100 mm culture 
Petri dishes on day 3 and split further when necessary. 
Further cycles of re-stimulation were performed to increase the number of T cells for the 
maintenance of the cell line. The MBP-specific CD4+ T cell lines expressing GFP or 





3.2.4 Cryo-conservation of the T cell line 
For cryo-conservation, 10-30 x 106 T cells were pelleted and then resuspended in 1.5 ml 
freezing medium on days 2, 6 or 7 after restimulation and aliquoted in cryotubes (Nunc, 
Thermo Fischer Scientific Inc., Waltham, US). These tubes were placed in freezing 
containers for cryo-conservation (Nunc, Thermo Fischer Scientific Inc., Waltham, US) and 
frozen at -80 °C. For long-term storage T cells were transferred into liquid nitrogen. 
3.2.5 Thawing of cryo-conserved T cells 
Cryo-conserved T cells were taken out of the liquid nitrogen and the cryotubes were kept 
for a few minutes at room temperature or incubated at 37°C in a water bath. Afterward, 
the cell suspension was diluted 1:10 in EH + 10% FCS, the T cells were counted, 
centrifuged and then used for further analyses or experiments. 
3.2.6 T cell counting 
The number of cells within a cell suspension was determined using a Neubauer 
hemocytometer (TH Geyer). The cell suspension was diluted in trypan blue (Sigma 
Aldrich, Munich, Germany) and then 10 µl of the dilution were applied to the 
hemocytometer. The living cells were counted within the four quadrants of the grid and 
the total cell number was calculated using the following equation: 
Counted cells/Number of quadrants * dilution factor * 104 = number of cells/ml. 
 
3.3 Cell isolation from different Lewis rat organs 
Rats were sacrificed by CO2 inhalation. The animal abdomen and chest were cut open 
from the ventral side of the body. Blood was collected directly from the heart of the 
animal by a syringe (BBraun, Omnifix) prefilled with 250 μl EDTA 80 mM and kept at 
room temperature until further processing. Moreover, several lymph nodes (cervical, 
popliteal, inguinal, para-aortal, mediastinal), the small intestine from the gut, and the 
spleen were extracted. Afterward, the animal was cut open from the dorsal side of the 




cord (SC) which was then removed. The meninges was stripped off the spinal cord and 
kept separately it. 
The skull of the animal was cut from the occipital to the frontal bone in a rostral direction 
and then removed. The brain was then extracted and the meninges stripped off and kept 
separately.  
All the dissected organs were kept on ice in EH medium. Finally, in order to measure the 
number of T cells inside the organs, the different tissues were weighed before being 
processed.  
Blood. Isolation of lymphocytes from blood was obtained by a density gradient based on 
Ficoll and sodium diatrizoate (Lymphocyte Separation Medium, Lonza, Walkersville, US): 
the blood was diluted with PBS 1X up to 10 ml and then gently placed above a layer of 5 
ml lymphocyte separation medium (LSM 1077) in a 14 ml tube (Greiner Bio-One). The 
sample was centrifuged for 30 min with 2000 rpm at room temperature with minimal 
acceleration/deceleration. Afterwards, the lymphocyte interphase, visible as a ring in the 
clear fraction of the gradient, was collected and placed into a new tube. After washing 
with PBS 1X the cells were resuspended in 1 ml EH medium. When necessary, in order to 
better purify the lymphocyte population we performed erythrolysis. To this end, after the 
washing step, the cells were incubated in 1 ml ACK buffer on ice for 3 minutes, washed 
again with PBS 1X and resuspended in EH medium. 
Spleen. A single cell suspension was prepared by smashing the spleen through a metal 
mesh (provided by UMG Göttingen, in-house machine shop) in EH medium. The 
homogenized organ was centrifuged for 6 minutes with 1200 rpm at 4 °C. Afterward, the 
cell pellet was incubated on ice for 3 min in 5 ml of ACK buffer in order to lyse the 
erythrocytes, then washed with 50 ml PBS 1X and resuspended in 10 ml EH medium, 
filtered through a 70 µm cell strainer (Greiner Bio-One), centrifuged and suspended again 
in 5 ml EH medium for further analyses.  
Lymph nodes. The isolation of cells from the LNs was achieved by smashing them through 
the metal grid in EH medium, centrifuging the flow-through for 6 minutes with 1200 rpm 
at 4 °C and resuspending the cell pellet in1 ml EH medium. 
CNS parenchyma and meninges. The isolation of cells from CNS (spinal cord or brain) 




through a metal grid, suspended in 12.5 ml of cold EH medium and vigorously mixed with 
5 ml of isotonic Percoll (1.124 g/L density) in a 50 ml tube (Greiner Bio-One). The cell 
suspension was centrifuged for 30 minutes with 2780 rpm at room temperature with 
minimal acceleration/deceleration. After one washing step in 50 ml PBS 1X, the cells were 
resuspended in 1 ml EH medium for further analyses.  
In order to count the T cells present inside the CNS in naïve conditions, we needed to 
remove the blood to avoid interference with such a small number of cells. For this 
purpose, after euthanizing the rat with CO2, the heart was exposed and deprived of the 
pericard. We performed an incision in the left ventricle where a cannula connected to a 
pump via flexible tubes (ISM596B, Ismatec, Wertheim, Germany) was inserted and fixed 
with a clamp. Finally, we performed another incision in the right atrium to intercept the 
blood circulation and started to pump PBS 1X through the cannula at a flow-rate of 
10.71 m/s to flush out the blood. 
Gut. The extraction of the small intestine and the isolation of intraepithelial lymphocytes 
(IEL) was performed as previously described (Reißig et al. 2014), through a procedure 
involving the combination of mechanical dissociation and enzymatic degradation of 
extracellular adhesion proteins. 
3.3.1 T cell magnetic activated cell sorting (MACS) isolation 
In the case of intrathecal injection or intravenous transfer of rMT-II T cells, or to improve 
the FACS sorting efficacy and velocity of fluorescent T cells, we performed MACS T cell 
isolation using two different kits: MACS Miltenyi Biotec for positive T cell selection, and 
EasySep Rat CD4+ T cell isolation kit (Stemcell technology) for negative selection. 
MACS Miltenyi Biotec (positive selection). The cells just extracted from the organs and 
suspended in EH medium were counted to ensure they were in the range between 107 
and 108 per organ. Afterwards, they were spun down and each cell pellet was incubated 
with 80 µl Pan T cell (OX52) microbeads in 1100 µl MACS buffer for 20 minutes at 4°C. 
After centrifugation for 10 minutes with 300xg at 4°C, the pellet was resuspended in 1 ml 
MACS buffer and the suspension applied into a MACS LS column previously rinsed with 
buffer and placed on a magnetic separator. Subsequently, the column was washed 4 or 5 
times with 1 ml of MACS buffer and the flow-through discarded. In the end, the column 




so that the magnetically labeled T cells could be flushed out by pushing a plunger into the 
column and then collected in a new collection tube. 
EasySep Rat CD4+ T cell isolation kit (negative selection). Firstly, the cells extracted from 
blood, spleen and LNs were counted. After centrifugation, they were then resuspended in 
MACS buffer with a ratio of 5*107 cells/ml and collected into a 14 ml tube. Afterwards, 
the supplied isolation cocktail for CD4 T cell negative isolation was added in a 
concentration of 25 µl/ml. After 10 minutes of incubation at room temperature, the 
supplied Vortex RapidSpheres were added to the sample (25µl/ml) which in turn was 
topped up with MACS buffer to 5 or 10 ml, depending on the initial volume (to 5 ml for 
samples ≤ 2 ml; to 10 ml for samples > 2 ml). Immediately after this the tube was placed 
right into a magnet (EasySep magnet, Stemcell Technologies Inc) for 3 minutes at room 
temperature. Finally, the enriched T cell suspension was poured into a new collection 
tube and used for further experiments or analyses. 
 
3.4 Characterization of T cell phenotype and activation 
The cells were analyzed directly after isolation from organs or after being harvested from 
culture in Petri dishes, in order to ascertain their phenotype or their activation by 
antibody-staining for cell surface markers. In addition, T cells were also sorted by FACS 
and collected for gene expression and protein analyses. 
Part of the cells was stimulated in vitro. 50.000 T cells were seeded into each well of a flat 
bottom 96-well plate and stimulated with 106 30-Gy irradiated thymocytes and the 
indicated concentrations of antigen. 
When stimulated by antibodies, the wells of a flat bottom 96-well plate were coated with 
α-CD28 and α-CD3 antibodies diluted in 30 µl of PBS at concentrations indicated in the 
table 3. After one day, 200.000 T cells were added to each well. 
In both the cases, the cells were kept under 10 % CO2 humidified atmosphere at 37 °C.  
For either stimulations, the cells were collected at different time points in order to 
analyze the level of their activation by staining for cell surface markers or intracellular 
staining for IFNγ and, at the same time, some cells were collected and lysed with Qiazol 




for enzyme-linked immunosorbent assay (ELISA). For proliferation assay, T cells were 
labelled by eFluor 670 (2,5µM) prior to stimulation. 
3.4.1 Antibodies (Ab)s and counting beads 
 
Primary target Host Clone Label Dilution Company Used as, for 
α rat αβTCR mouse R73 AlexaFluor 647 1:300 Biolegend 
Primary Ab, FACS 
staining and sorting 
α rat CD62L mouse OX-85 PE 1:200 Biolegend 
Primary Ab, FACS 
staining and sorting 
α rat CD25 mouse OX-39 PE 1:200 Biolegend 
Primary Ab, FACS 
staining 
α rat CD11b/c mouse OX-42 AlexaFluor 647 1:200 
AbD 
Serotec 
Primary Ab, FACS 
staining 
α rat CD25 mouse - biotinylated 1:100 
AbD 
Serotec 
Primary Ab, FACS 
staining 
α rat CD134 mouse OX-40 biotinylated 1:100 
AbD 
Serotec 
Primary Ab, FACS 
staining 
α rat IFNγ mouse DB-1 - 1:100 Biolegend 
Primary Ab, FACS 
intracellular 
staining 






stimulation by Abs 






stimulation by Abs 
α rat IFNγ goat - - 1:200 Peprotech Capture Ab, ELISA 
α rat IL-2 rabbit - - 1:200 Peprotech Capture Ab, ELISA 
α rat IFNγ goat - biotinylated 1:100 Peprotech Detection Ab, ELISA 



















α-mouse Goat - APC 1:200 
JacksonImm 
Research 
Secondary Ab, FACS 
staining 
Streptavidin-APC - - APC 1:400 
BD 
Biosciences 
Secondary Ab, FACS 
staining 
Streptavidin-PECy5 - - PE-Cy5 1:400 Biolegend 
Secondary Ab, FACS 
staining 










3.4.2 FACS analysis of the antibody staining of cell surface markers and cell 
count 
In order to perform cell surface staining with fluorescently labeled antibodies, the cells 
were incubated on ice for 15 minutes with the required primary antibodies diluted as 
mentioned (Table 3) in 100 µl FACS buffer. Afterward, the cells were centrifuged for 
3 min with 1300 rpm at 4°C and either incubated on ice with a secondary antibody 
diluted in 100 µl FACS buffer for about 20 min, or directly resuspended in 200 - 300 µl 
FACS buffer and then transferred into 5 ml FACS tubes (BD Biosciences, San Jose, CA, US) 
for analysis. All the incubation steps were performed in the dark. In order to detect the 
number of cells, 50 µl of FACS buffer with a precise number of fluorescent counting beads 
was added to the top of the 200 µl suspension, and the number of the required cells was 
calculated in relation to the number of beads. 
FACS analysis was performed using a flow cytometer FACS Calibur instrument (BD 
Biosciences, San Jose, CA, USA). This system consists of two lasers, a red diode laser (640 
nm excitation) and an air-cooled argon laser (488 nm excitation) that make possible to 
measure four fluorescent parameters.  
The flow cytometer BD FACS AriaIII (BD Biosciences, San Jose, CA, USA) was also used 
FACS analysis. 
3.4.3 Intracellular staining 
48 hours after stimulation, the cells were treated for 3 hours at 37°C in incubator with 5 
µg/ml Brefeldin A (Sigma Aldrich, Munich, Germany) in RM to trap the intracellular 
cytokines in the Golgi apparatus. 
After that, the cells were centrifuged and then fixed with 2% PFA (Roth) for 20 minutes 
on ice. After a washing step with PBS 1X, and another with 1X BD Perm/Wash buffer (BD 
Biosciences, San Jose, CA, US), they have been resuspended in 1X BD Perm/Wash buffer 
plus 5% rat serum and kept on ice for 30 minutes. Afterward, the cells were incubated 
with α-rat IFNγ Ab diluted as indicated (Table 3) in the same buffer, then washed one 
time and incubated again for 90 minutes on ice with the APC-conjugated secondary Ab. 
Subsequently, they were washed with 1X BD Perm/Wash buffer plus 5% rat serum, 





3.4.4 Proliferation assay 
To check the proliferation of the cells after stimulation, we used the cell proliferation dye 
eFluor 670 (eBioscience) and proceeded according to the supplied protocol: 
Approximately 10x106 cells were washed two times with PBS 1X to remove any serum 
and then resuspended in 1 ml PBS 1X. Afterwards, an equal volume of a 10 µM solution 
of cell proliferation dye eFluor 670 in PBS1X was added on the suspension in order to 
reach a 2,5 µM final concentration of the dye eFluor 670. After that, the cells were kept 
for 10 minutes at 37°C in the dark and then the labelling was stopped by the addition of 
10 ml PBS + 10% FCS. Finally, the cells were washed 3 times with EH + 10% FCS and then 
resuspended in RM and stimulated as desired. 
3.4.5 Enzyme-like immunosorbent assay (ELISA) 
The supernatant of in vitro stimulated T cells was collected at different time points, and 
the concentration of produced cytokines was analyzed and measured by ELISA. 
96-well plates with a polystyrene-based surface (Nunc, Thermo Fischer Scientific Inc., 
Waltham, US) were coated with cytokine-specific capture antibodies diluted in PBS 
overnight at room temperature. The next day, the plate was washed 4 times with ELISA 
washing buffer (Table 1) and then was incubated with 300 µl of blocking buffer (Table 
1) in each well for 1 hour at room temperature. After 4 washing steps with washing buffer, 
a volume of supernatant (40 µl to measure IFNγ and 100 µl to measure IL-2) was loaded 
on each well. Also, a serial dilution of standard cytokines (Peprotech) was loaded on other 
wells in order to favor the measurement of the concentration of the cytokines inside the 
T cell supernatant. The incubation was kept for 2 hours at room temperature. 
After 4 washing steps, the wells were incubated for 2 hours at room temperature with 
detection antibodies specific for the desired cytokines, diluted in 100 µl of blocking buffer. 
Afterwards, the plate was washed again for 4 times and then incubated for 30 min at 
room temperature with the enzyme horseradish peroxidase (HRP)-conjugated 
streptavidin diluted in 100 µl.  
After an extensive washing, the substrate tetramethylbenzidine (TMB) (BD Biosciences), 
coupled to H2O2, was added in each well (100 µl) and allowed to react in the dark for 
maximum 30 minutes. HRP catalyzes the oxidation of TMB to benzidine blue. The reaction 




was measured with a SUNRISE ELISA reader (TECAN) at 450 nm wavelength and the 
software Magellan 6. 
In order to calculate the cytokine concentration in the supernatants, the optical density 
of each sample was correlated with that of each dilution of the standard cytokines. 
3.4.6 FACS sorting 
For cell sorting, we used a flow cytometer BD FACS AriaIII (BD Biosciences, San Jose, CA, 
USA), equipped with a four-laser system (488 nm, 561 nm, 633 nm, and UV).  
The cells were taken up in 500 µl EH medium with 1mM EDTA and, when necessary, 
stained with α-rat AlexaFluor 647-αβTCR Ab, together or not with α-rat PE-CD62L Ab, 
and then sorted for the expression of GFP, mCherry and the stained surface molecules, 
alone or in combination. The sorting process was performed at minimum flow-rate of 
1000-2000 events/second and at 4°C. This made it possible to reach a purity of 90-95 % 
for the selected populations. During the sorting process, the cells were collected in 5 ml 
tubes containing fresh RM. When the required number of cells was reached, the collected 
cells were centrifuged and used for further analyses. 
3.4.7 Analysis of gene expression 
3.4.7.1 RNA extraction 
In order to quantify the expression of the genes of interest, we performed an RNA 
extraction from collected cells. 
The T cells collected directly from in vitro cultures or sorted by FACS were centrifuged 
and resuspended in 100 µl Quiazol Lysis reagent (Qiagen) by repetitive pipetting to 
induce cell lysis. Afterwards, the samples were stored at -80°C. 
After some days, the samples were shaken and left for 5 minutes at room temperature to 
permit the complete dissociation of the nucleoprotein complex. Subsequently, 20 µl of 
chloroform (Roth) were added and after vigorous shaking for 15 seconds, the samples 
were incubated for 3 minutes at room temperature. Afterward, the samples were 
centrifuged at 12.000xg for 15 min at 4°C. By centrifugation, the samples were separated 
into a lower phenol-chloroform phase, an interphase, and an upper aqueous phase 
containing the RNA. For this reason, the upper phase was transferred to a new tube, and 




of incubation at room temperature, the samples were centrifuged at 12000xg for 10 
minutes at 4°C. The precipitated RNA formed a gel-like pellet so that the supernatant 
could be easily removed. 
In order to dissolve the RNA, the pellet was washed with 100 µl of 75% ethanol (Roth). 
Afterward, the sample was mixed by brief vortexing and then centrifuged at 7.500xg for 
5 min at 4°C. 
Afterwards, the supernatant was removed and the pellet was dried until ethanol 
evaporation. Finally, the RNA pellet was dissolved in 11 µl of RNase-free water (Qiagen) 
and stored at -80°C or directly used for subsequent enzymatic reactions. 
3.4.7.2 Reverse transcription: complementary DNA (cDNA) synthesis 
The synthesis of cDNA from the extracted RNA was performed following the 
manufacturer’s instructions for the Fermentas RevertAidTM First Strand cDNA Synthesis 
Kit (Thermo Fischer Scientific Inc., Waltham, US). 
1 µl of random hexamer primers was pipetted and mixed in the 11 µl RNA sample. These 
primers bind to the RNA non-specifically and therefore can synthesize cDNA from all 
possible RNA templates. 
Afterwards, the RNA-primer mix was incubated at 65°C for 5 minutes and then cooled on 
ice for a further 5 minutes.  
In the meanwhile, the following components of the kit were combined and mixed to form 
a master mix:  
Per each RNA sample, 4 μl 5x Reaction Buffer, 2 μl 10mM dNTP Mix, 1 μl RiboLockTM 
RNase Inhibitor and 1 μl RevertAidTM MMuLV Reverse Transcriptase.  
8 μl of the master mix were added to the RNA-primer mix and all the solution was 
transferred in new small tubes that in turn were loaded in thermal cycler (Eppendorf 
Mastercycler EP Gradient) in order to perform the following reactions leading to new 
cDNA synthesis: 
Firstly, the samples were incubated at 25°C for 5 min. The cDNA synthesis was promoted 
by a subsequent 60-minute incubation at 42°C.The cDNA synthesis was stopped through 
heat inactivation of the enzyme at 70°C for 5 minutes.  






3.4.7.3 Real time polymerase chain reaction (PCR) 
The gene expression analysis was achieved by real time (or quantitative) PCR (qPCR) 
using the StepOnePlus Real Time PCR System and the StepOne Software v2.0 (Applied 
Biosystems, Darmstadt, Germany).  
Per each gene of interest, custom designed real time PCR primers and probes (Table 4) 
were purchased from Sigma Aldrich (Munich, Germany) or from Microsynth, with FAM-
TAMRA as fluorophore-quencher pairs. Beta-actin (β-actin) was used as a constitutively 
expressed gene (housekeeping gene). 
The single strand cDNA of interest was diluted 1:20 with RNase-free water and 7.5 µl of 
the solution were mixed with 12.5 µl of ready-to-use real time PCR Master Mix (including 
dNTPs/dUTPs, HotGoldStar DNA polymerase, 5 mM final MgCl2 concentration; 
Eurogentec, Seraing, Belgium) and 5 µl of Primer-Probe mixture and finally loaded into 
one well of a 96-well real time PCR plate (Sarstedt AG & Co, Nümbrecht, Germany) for a 
40 cycles real time PCR run. 
In the end, the 2^-ΔCt method was used for the quantification of the expression of the 
gene of interest in relation to the one of the housekeeping gene, β-actin. 
 
Gene Oligonucleotide sequences 
β-actin 
Fw: 5’-GTA CAA CCT CCT TGC AGC TCC T -3’  
Rev: 5’-TTG TCG ACG ACG AGC GC -3’   
Probe: 5’-Fam-CGC CAC CAG TTC GCC ATG GAT -Tamra-3’ 
IFNγ 
Fw: 5’-AAC AGT AAA GCA AAA AAG GAT GCA TT -3’  
Rev: 5’-TTC ATT GAC AGC TTT GTG CTG G -3’  
Probe: 5’-Fam-CGC CAA GTT CGA GGT GAA CAA CCC -Tamra-3’ 
IL-17 
Fw: 5’-GAG TCC CCG GAG AAT TCC AT -3’  
Rev: 5’-GAG TAC CGC TGC CTT CAC TGT -3’ 
Probe: 5’-Fam-ATG TGC CTG ATG CTG TT -Tamra-3’ 
IL-2 
Fw: 5’-CTC CCC ATG ATG CTC ACG TT-3’ 
Rev: 5’-TCA TTT TCC AGG CAC TGA AGA TG-3’ 
Probe: 5’-Fam-CAA TTC TGT GGC CTG CTT GG -Tamra-3’ 
GM-CSF 
Fw: 5’-TCC TAA ATG ACA TGC GTG CT-3’ 
Rev: 5’-CCC GTA GAC CCT GCT TGT AT-3’ 
Probe: 5’-Fam-TGT GCA GAC CCG CCT GAA GC-Tamra-3’ 
CD25 
Fw: 5’-CAC AGT CTG TGT ACC AGG AGA ACC T-3’ 
Rev: 5’-CCA CGA AGT GGT AGA TTC TCT TGG-3’ 
Probe: 5’-Fam-CAG GTC ACT GCA GGG AGC CCC C-Tamra-3’ 
Hif1α 
Fw: 5’-TCC TGCA CTGA ATC AAG AGG-3’ 
Rev: 5’-AGG ACT TGC TG GCT GA TCTT-3’ 
Probe: 5’-Fam-TCC CAG TGA CTC TGG GCT TGA CTC-Tamra-3’ 
Irf4 
Fw: 5’-CTC CGA CCC ATA CAA GGT CT-3’ 
Rev: 5’-CAA AG TGA GCT GCT TTG CTC-3’ 





Fw: 5’-ACC CTC TTC AGA GGA CGA GA-3’ 
Rev: 5’-GGA GGA CTC TGT GGG TGA GT-3’ 
Probe: 5’-Fam-CCG CAG AAA TCC GAC TGC CA-Tamra-3’ 
HK-1 
Fw: 5’-ACG CTG ATG GAG GTG AAG AA-3’ 
Rev: 5’-TAC CAG CAG AAC CCG GAA AT-3’ 
Probe: 5’-Fam-TCC CAT CCG GGA TGC TCC GGA-Tamra-3’ 
LdhA 
Fw: 5’-ACG GAT GCA GAC AAG GAG CA-3’ 
Rev: 5’-AAT GGG ATG CAC CCG CCT AA-3’ 
Probe: 5’-Fam-TGG GCC ATT GGC CTC TCC GTG GCA-Tamra-3’ 
Eno 1 
Fw: 5’-ACC CAG TGG TGT CCA TTG AA-3’ 
Rev: 5’-TGG TCA CTG TGA GGT CAT CC-3’ 
Probe: 5’-Fam-CCC ACC ACC TGG ATG CCT GCA-Tamra-3’ 
cMyc 
Fw: 5’-CCC CTA GTG CTG CAT GAA GAG-3’ 
Rev: 5’-TCC ACA GAC ACC ACA TCA ATT TC-3’ 
Probe: 5’-Fam-CAC CAC CAG CAG CGA CTC TGA AGA AG-Tamra-3’ 
Table 4 Primer and probe sequences for real time PCR. 
 
3.5 Characterization of the glycolysis phenotype 
3.5.1 Extracellular acidification rate (ECAR) assay 
We used the Agilent Seahorse XF Glycolysis stress test kit in order to assess the glycolytic 
flux in the cells.  
The glycolytic conversion of glucose to pyruvate, and subsequently lactate, results in a 
net extrusion of protons into the extracellular medium. This results in the acidification of 
the medium surrounding the cells. The XF instrument measures the acidification rate and 
reports this as ECAR. The stimulation of glycolysis by glucose administration and its 
subsequent inhibition by 2-DG allows to measure the acidification caused by the 
glycolytic release of lactate thereby reporting the rate of glycolysis.  
We proceeded as recommended in the manufacturer’s kit. In the day prior to assay, the 
Seahorse XF Analyzer was turned on to let it warm up and stabilize; the Seahorse XF 
Microplate was coated with collagen 10 µg/ml diluted in PBS overnight at 4°C; finally, the 
sensor cartridge was hydrated in Seahorse XF Calibrant at 37°C in a non-CO2 incubator 
overnight. 
On the day of the assay, the Seahorse XF Base Medium (without glucose) was 
supplemented with 1 mM glutamine, warmed up to 37 °C and adjusted to pH 7.4 (assay 
medium). Afterwards, 300000 T cells diluted in 180 µl of prepared assay medium were 
plated in each well of the coated Seahorse XF Microplate. This was incubated in a 37°C 




supplied glucose and 2-DG were diluted in the assay medium at the desired 
concentrations and then loaded into the injection ports of the sensor cartridge in such a 
way as to achieve the final concentrations of 10mM glucose and 100mM 2-DG per well. 
Afterwards, a utility plate with the loaded sensor cartridge was placed on the XF analyzer 
tray for 15-30 minutes calibration. Finally, the utility plate was replaced with the cell 
culture Seahorse XF Microplate and the glycolysis stress test was started by the XF 
software. All the measurements of ECAR over time and after glucose (acidification due to 
glycolysis) or 2-DG (non-glycolytic acidification) treatments were stored in an Excel 
spreadsheet and then all the data analyzed in order to assess the glycolysis rate (ECAR 
after glucose – ECAR after 2-DG) of each cell population under analysis. 
3.5.2 Glucose uptake assay 
The measurement of the glucose uptake level of T cells was achieved by the use of the 
Glucose Uptake Cell-Based Assay Kit reagents purchased from Cayman Chemical. 
After in vitro cultured T cells were harvested , they were washed once in glucose-free 
DMEM. Afterwards, 250000 cells per well were plated in a V96 well plate (Thermo Fisher 
Scientific), and incubated with 150 µg/ml of the fluorescently-tagged glucose derivative 
(2-NBDG) diluted in 100 µl glucose-free DMEM. The non-stained T cells used as control 
were kept in 100 µl of their culture medium. After 3 hours of incubation in a 10% CO2 
incubator at 37°C, the cells were centrifuged at room temperature at 1400 rpm for 4 
minutes and then washed with 200 µl of the supplied cell-based assay buffer. After a new 
centrifugation, they were resuspended in 200 µl of FACS buffer and analyzed by a 
cytometers FACS AriaIII or CytoFLEX (Beckman Coulter Life Sciences). 2-NBDG is 
detectable at excitation and emission wavelengths of 485 and 535 nm respectively. 
The cells stained ex vivo were incubated for only 50 minutes in EH medium. After 
centrifugation and a washing step in Cell-Based Assay buffer, they were further stained 
with AlexaFluor 647-conjugated α-rat αβTCR Ab in 100 µl FACS buffer (1:300). After 15 
minutes of incubation on ice, the cells were centrifuged, washed and then resuspended in 








3.5.3 Western blot analysis 
The quantification of the protein expression of glycolytic enzymes was achieved by 
western blot conducted in the lab of Prof. Giuseppe Matarese at the Department of 
Molecular Medicine and Medical Biotechnology of the University of Napoli, “Federico II”.  
At least 200000 T cells per sample were sorted and immediately centrifuged. The 
supernatant was removed and the pellet frozen at -80°C. Afterward, every pellet was 
shipped to Prof Matarese’s laboratory for western blot analysis.  
Briefly, total cell lysates were obtained incubating cells at 4°C for 20 minutes in  Ripa 
Buffer (R0278; Sigma Aldrich), plus SigmaFast protease inhibitor (S8820; Sigma Aldrich) 
and Sigma phosphatase inhibitor (P5726; Sigma Aldrich). Immunoblot analysis was 
performed as previously described (De Rosa et al. 2007). The antibodies used were the 
following: anti-enolase, anti-hexokinase, anti-PKM1/2 (pyruvate kinase isozymes 
M1/M2), anti-FAsyn (fatty acid synthase), anti-apoA4 (apolipoprotein A-IV), anti-ACAT2 
(Acetyl-CoA C-acetyltransferase 2) (1:500 dilution from Abcam), anti-pS6 (phospho-S6 
ribosomal protein), anti-DLAT (dihydrolipoamide S-Acetyltransferase) and anti-SDHA 
(Succinate dehydrogenase complex flavoprotein subunit) (1:1000 dilution and from Cell 
Signaling Technology). Anti-β-actin (1:1000 dilution from Santa Cruz Biotechnology) and 
anti-S6 (S6 ribosomal protein) antibodies were used to normalize the amount of loaded 
protein. All filters were quantified by densitometric analysis. 
 
3.6 Animal experiments 
3.6.1 Animals, caretaking and maintenance 
All the experimental animals used for this study were rats with the Lewis rats genetic 
background,. namely, wild-type (WT), rMT-II and rOT-II rats. They were all obtained from 
the animal facility of the University Medical Center Göttingen (UMG) and kept under 
standardized conditions. The animal experiments were performed according to the local 






3.6.2 Generation of “memory” Lewis rats 
The creation of “memory” Lewis rats was achieved as previously described (Kawakami 
et al. 2005). Intraperitoneal transfer of TMBP GFP cells (2 x 106 cells, in 0.5 ml/animal in EH 
medium) into newborns was performed under hypothermia within 48 hours after birth. 
After T cell transfer, the pups were kept under a 30°C humid atmosphere and returned to 
the mother only when fully recovered. The T cells were transferred 5 or 6 days after in 
vitro restimulation. 
3.6.3 Active EAE induction 
Active EAE was induced by subcutaneous immunization of rats with guinea pig MBP 
protein (1 mg/ml in PBS) emulsified in an equal volume of complete Freund’s adjuvant 
(CFA) containing Mycobacterium tuberculosis H37Ra (Difco, Becton Dickinson, Franklin 
Lakes, NJ, USA) (2 mg/ml in mineral oil). This emulsion was prepared with two tuberculin 
glass syringes (POULTEN & GRAF GmbH, Wertheim, Germany) joint via a custom-made 
connector.  
150 µl of the emulsion were injected subcutaneously into the tail base (50 µl on each side) 
and into the hind limb popliteal cavity (25 µl on each side) of rats anesthetized by diethyl 
ether (Roth). 
3.6.4 Induction of transfer EAE 
To induce transfer EAE, fully activated MBP-reactive CD4 T cell blasts of a T cell line, 
collected on the day 2 after in vitro restimulation  (from 2 to 5 x 106 cells in 1 ml of EH 
medium per rat) were injected by a 1 ml syringe (Omnifix) into the tail vein of Lewis rats 
anesthetized with diethyl ether. 
3.6.5 Scoring system for EAE induced in rats 
After transfer or active EAE induction, the rats were weighed and scored daily (or several 








- 0: No symptoms. 
- 0.5: Partial loss of tail tonus. 
- 1: Flaccid tail (complete loss of tail tonus). 
- 1.5: Flaccid tail and subtle gait disturbance. 
- 2: Pronounced weakness of hind limbs, progressed gait disturbance. 
- 2.5: Pronounced weakness of hind limbs, impaired adduction of hind limbs, paralysis 
of a single hind limb. 
- 3: Paraplegia (complete hind limb paresis); animals are able to actively move forward 
using their forelimbs. 
- 3.5: Weakness of forelimbs leading to impaired forward movement. 
- 4: Tetraplegia. 
- 5: Moribund or dead. 
For animal welfare reasons animals with a score of 3.5 or higher were euthanized. 
3.6.6 Intrathecal injection 
In order to perform an intrathecal injection of T cells, rats were anesthetized by 
subcutaneous injection of xylazine (10 mg/kg) and ketamine (50 mg/kg). By a 
stereotactic device the head of the rat was fixed by ear bars and secured by the tooth 
holder. The T cells, diluted in 30 µl EH medium were injected between the cervical 
vertebrae C1 and C2. After disinfection of the injection site with ethanol, a 0.5 ml 
tuberculin syringe (Becton Dickinson, Franklin River, NJ, USA) was fixed to the 
manipulator's arm and the needle was slowly inserted until the cerebrospinal fluid was 
reached. Afterward, the total volume of 30 µl was injected over a time period of 
10 minutes. 
 
3.7 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 7 software (GraphPad 
Software Inc., San Diego, CA, US). For all analyses, the student’s t-test was used and the p-
value was shown as follows: 
p-value > 0.05: ns; p-value ≤ 0.05: *; p-value ≤ 0.01: **; p-value ≤ 0.001: ***; p-value ≤ 





4.1 rMT-II rats do not develop any spontaneous EAE and do not show 
any aggravation of the adoptive transfer EAE compared to the wild type 
controls 
We followed more than 1000 homozygous rMT-II rats ranging in age from two months 
up to one year, however none of those animals spontaneously developed neurologic 
symptoms. This could not be explained by the loss of transgene expression, as this strain 
has maintained GFP expression in all blood cells, dominance of TCR-Vβ8.2 in T cell 
repertoire and responsiveness to MBP ex vivo over many generations (data not shown).  
It is known that during transfer EAE the injected auto-reactive T cells are able to break 
the BBB, infiltrate the CNS and get re-activated locally by encountering APCs presenting 
autoantigen (Lodygin et al. 2013). The activation of T and APC cells inside the CNS guides 
the recruitment of the endogenous immune cells to the CNS. Among them, the recruited 
T cells can be either not auto-reactive or be specific for another auto-antigen. In the first 
case, they will either not be activated (Owens et al. 1998; Krakowski and Owens 2000) 
or, possibly, will undergo a bystander activation (Nogai et al. 2005), whereas in the 
second case, they can be activated by antigen due to determinant spreading (Owens et al. 
1998; McLaughlin et al. 2015) Therefore, the recruited T cells could to some extent 
contribute to the inflammation pulse and the expansion of the tissue damage seen in EAE. 
In rMT-II rats most of the CD4+ T cells are MBP-reactive, and once recruited into the CNS 
they are expected to strongly contribute to the inflammation pulse via antigen-specific 
activation (Busch et al. 2000; Owens et al. 1998), leading to a higher and/or faster 
expansion of the tissue damage and aggravated clinical picture. 
Surprisingly, we did not observe any aggravation of transfer EAE in rMT-II compared to 
WT rats during entire course of the disease induced by injection of MBP-reactive CD4+ 






FIG 1 Clinical course of transfer EAE in rMT-II and WT rats. 
Transfer EAE in rMT-II or WT rats (n = 3) was induced by injection of 2 x 106 TMBP cells. (A) Clinical score 
and (B) percentage of weight variation in each rat were measured daily after transfer, until complete 
recovery. This is a representative experiment of n = 3 experiments with different TMBP cell lines (including 
rMT-II derived) and dose of transferred cells. Data are presented as mean ± SD; Statistical analysis was 
performed by student’s t test. 
 
4.2 Primary rMT-II T cells are highly encephalopathogenic when 
undergoing peripheral activation in vivo 
In order to explain this passivity of the MBP-specific T cells within the immune repertoire 
of rMT-II rats we next tested whether rMT-II T cells can be activated in vivo by 
immunization with guinea pig MBP and induce clinical disease. To this end, rMT-II rats 
and age-matching WT controls were subcutaneously (s.c.) immunized with MBP 
emulsified in CFA. In WT animals this protocol as expected evoked monophasic paralytic 
disease with onset 10 days after immunization (FIG 2A and B). Immunization of rMT-II 
animals also induced clinical EAE with 100% incidence as with in WT controls, however 
with a clearly accelerated onset (day 6), higher severity and more protracted recovery 
phase (FIG 2A-C). 
These in vivo data exclude an anergic state of rMT-II T cells. Moreover, here we have 
demonstrated that rMT-II T cells get primed much earlier than WT T cells after MBP 
immunization, are able to migrate into the CNS and represent the main drivers of a highly 






FIG 2 Comparison of active EAE in rMT-II and WT Lewis rats.  
(A,B) WT and homozygous rMT-II rats were immunized in parallel with the same dose of MBP in CFA. The 
clinical score (scale 1-5; see METHODS for details) and body weight were measured daily (n = 3 per group). 
(C) Averaged clinical score (mean ± SEM; upper Y axis) and weight change (lower Y axis) measured over 
entire period (from 0 to 28 days after MBP immunization) shown in (A) and (B). ** - P ≤ 0.01; *** - P ≤ 0.001 
by student’s t test; ns – not significant (p values and corresponding asterisks are listed in the paragraph 
“3.7 statistical analysis” of materials and methods). 
 
Further we asked whether enhanced active EAE disease in rMT-II rats was mostly 
attributed to the transgenic MBP-reactive T cells. We transferred T cells isolated from a 
pool of lymph nodes (LNs), spleens and blood of naïve rMT-II rats into WT animals. One 
day after transfer, the animals were immunized with MBP in CFA. Also in this case, WT 
animals receiving transgenic rMT-II T cells showed the first symptoms about three days 
earlier than the non-transferred control rats (FIG 3A-C). Therefore, the T cell repertoire 
of naïve rMT-II rats obviously contains a component able to accelerate active EAE, but 
would this cellular population suffice to induce disease in a host resistant to active EAE? 
To address this question we used ovalbumin-specific TCR-transgenic Lewis strain rOT-II 
as a host for adoptive transfer and subsequent MBP-immunization (FIG 3D). Because T 




ovalbumin, upon active immunization with MBP this strain is virtually disease resistant 
(Lodygin, Kitz et al. unpublished). We transferred isolated rMT-II or rOT-II T cells into 
rOT-II recipient rats and immunized them with MBP in CFA (FIG 3D). The transfer of 
rMT-II, but not rOT-II T cells fully restored susceptibility of the rOT-II strain to active EAE 
(FIG 3E and F). Moreover, the onset of clinical disease mediated by the transfer of rMT-
II T cells was accelerated relative to the onset of active EAE in WT controls (FIG 3E and 
F) resembling the earlier manifestation of disease observed in former experiments (FIG 
2A and B, FIG 3B and C).   
Thus, we have demonstrated that TCR transgenic rMT-II T cells become efficiently primed 
after immunization and can more rapidly acquire pathogenic properties allowing for 
migration into the CNS and initiation of inflammatory process than MBP-reactive 






FIG 3 Adoptive transfer of rMT-II T cells prior to immunization confers susceptibility to active EAE.  
(A) Outline of the experimental approach in transfer/immunization experiment using WT host. T cells were 
magnetically isolated from indicated organs and transferred i.v. into WT recipient Lewis rats. On the next 




course (B) and the incidence of EAE (C) are shown.  Data are mean ± SEM (n = 5 for rMT-II transfer group 
and n = 3 for WT group without T cell transfer). (D) Outline of the experimental approach in 
transfer/immunization experiment using TCR transgenic rOT-II host. T cells were magnetically isolated 
from lymph nodes of rMT-II or rOT-II background and transferred i.v. into rOT-II recipient rats. On the next 
day, rOT-II rats that received indicated type of T cells along with control naïve animals were s.c. immunized 
with MBP in CFA. (E) Clinical course of EAE (mean ± SEM, n = 3 per group). Statistical significance 
determined by t-test (blue: rMT-II cells in rOT-II versus rOT-II cells in rOT-II. black: rMT-II cells in rOT-II 
versus WT (NO transfer)) (F) EAE incidence (same legend as in E). 
 
4.3 Effector T cell lines derived from rMT-II strain are highly sensitive 
to MBP stimulation in vitro 
MBP-reactive CD4 effector T cell line can be established from immunized Lewis rats and 
are widely used for the induction of tEAE (Ben-Nun et al. 1981). Effector T cell lines can 
be readily established from rMT-II rats. Upon exposure to MBP-presenting APCs these 
cell lines vigorously proliferate and they are strongly pathogenic after transfer to healthy 
recipient rats (Lodygin, Kitz et al. unpublished). During generation and propagation of 
such lines, T cells are subjected to multiple rounds of antigenic stimulation and become 
terminally differentiated. We asked how the in vitro antigenic response of effector rMT-
II T cell lines differs from the response of primary rMT-II T cells isolated ex vivo from 
naïve donors.   
To measure the antigenic response, equal numbers of resting effector T cells and primary 
T cells isolated from blood or lymph nodes were co-cultured with thymic APCs loaded 
with MBP at different concentrations. Then we performed a time course analysis of 
cytokine production by ELISA and qPCR over 48 h time period (FIG 4A-C). At each tested 
concentration of antigen, rMT-II effector T cells rapidly (from 6 h after stimulation on) 
increased secretion of IFNγ and the concentration of this cytokine remained high until 
the end of experiment. Primary rMT-II LN T cells showed only transient and very small 
peak of IFNγ production around 12 h time point. A similar discrepancy between effector 
T cell line and primary LN T cells was observed for the IL-2 cytokine release (FIG 4B).  
The transcriptional response to MBP stimulation was much higher in the effector cell line 
than in blood or LN derived T cells (FIG 4C). It reached its peak after around 6 h, and 




transcriptional response in blood and LNs T cells, even if much lower, was detected much 
later, at around 36 h  after stimulation (FIG 4C).  
The activation of LNs and blood rMT-II T cells by thymic APCs resulted in a very limited 
proliferation 72 h after stimulation, whereas these T cells vigorously proliferated in 
response to anti-CD3 and anti-CD28 antibody stimulation (FIG5 A). Additionally the 
CD25 expression in these cells increased after 48 hours and reached its peak in 72 hours 
with at all the antigen concentrations used. The maximal TCR stimulation by antibodies 
resulted, as expected, in a uniform increase of CD25 expression (FIG 5B).  
 




FIG 4 In vitro activation kinetic of different rMT-II T cell subsets. 
Time course of cytokine production determined by ELISA (A,B) and cytokine gene expression determined 
by quantitative reverse transcription polymerase chain reaction (RT-qPCR) (C). Concentration of IFNγ (A) 
and IL-2 (B) in supernatants collected at the indicated time after addition of antigen loaded APC was 
measured over 48 h period. MBP-specific effector line established from rMT-II (Teff cell line, in red) and 
primary T cells isolated from naïve rMT-II LNs (LN T cells, in green). The stimulation was performed in 
vitro with irradiated thymocytes in the presence of 100 µg/ml, 10 µg/ml and 1 µg/ml MBP. Data are mean 
± SD. (C) RNA isolated from stimulated cells at the indicated time point after stimulation was converted to 
cDNA and analyzed by TaqMan PCR with primers and probes specific for IFNγ and IL-2 gene transcripts. 
Shown is relative expression (mean ± SEM) normalized to the level of beta-actin gene expression. On the 
bottom plots the expression values for the cell line are not shown in order to reveal small scale changes in 




FIG 5 Activation of rMT-II T cells in vitro analyzed by flow cytometry.  
(A) Proliferation-dependent dilution of fluorescent dye eFluor670 measured by flow cytometry. Primary 
rMT-II T cells isolated from blood and LN were stimulated with antigen loaded thymic APCs or with 
monoclonal antibodies specific for CD3 and CD28 (color code shown in panel B) and analyzed on day 3 after 
stimulation. (B) Expression of CD25 activation marker on blood and LN derived rMT-II T cells determined 





4.4 Phenotype and CNS residence of rMT-II T cells under steady state 
condition 
The inability of rMT-II T cells to enter the tissue expressing the myelin target antigen in 
rMT-II rats might be a reason why these animals do not develop spontaneous 
autoimmunity. It is however known that the central nervous system, in spite being an 
immune-privileged organ, undergoes continues surveillance by immune cells (Deli et al. 
2005). We therefore asked whether MBP-specific rMT-II T cells can be detected in the 
CNS of healthy rats. We analyzed T cell frequency in the spinal cord (SC) of healthy rMT-
II rats (perfused with cold PBS to remove contaminating blood) and analyzed their 
immune phenotype. For comparison, we also analyzed T cells derived from immune 
organs such as blood, LN and non-immune organ, the gut.  
In fact, we observed in the SC the presence of T cells. Expectedly, compared to blood, LNs 
or a preparation of intraepithelial lymphocytes (IELs) from the small intestine the 
numbers of these CNS-derived T cells were very low. However, we could counted an 
average of 1136.7 ± 245.6 T cells per g of the total SC tissue including the meninges, of 
which an average of 327.6 ± 59.2 T cells per g were present in the SC parenchyma 
(separated from meninges) (FIG 6A). This result indicates that T cells in rMT-II rats 
contribute, albeit at low rate, to CNS immune-surveillance. CD62L (L-selectin) expression 
can distinguish naïve T cells from memory T cells. Staining of T cells recovered from the 
SC revealed that the vast majority of them were CD62L negative (96.7 ± 1.5%) and 
therefore likely to be memory T cells (FIG 6B). In contrast, CD62L+ naïve rMT-II T cells 
were abundantly present in the blood and LN, where this population is known to circulate 
and home, respectively. Interestingly, among gut IELs 95% of T cells were also CD62L 
negative, which confirms the concept that T cells residing in peripheral organs have a 
memory phenotype (Gebhardt et al. 2013). Further, we found that CD25 expression was 
increased in T cells recovered from SC relative to the levels detected in blood and LN T 
cells (FIG 6C), consistent with the assumption that SC-derived T cells belong to the 
memory subset. This findings can be interpreted in two ways. First, memory T cells 
preferentially (if not exclusively) gain access to and maintain residency in the healthy 
CNS. Second, naïve rMT-II T cells enter CNS tissue, recognize locally presented antigen 
and differentiate into memory type, thereby ceasing expression of CD62L and 




suggest. As evident from TCR staining of rMT-II cells in different organs, there are two 
distinct populations of T cells with high and intermediate expression level of αβTCR (FIG 
6A, see also FIG VII). TCRint cells uniformly express the TCR-Vβ8.2 chain whereas TCRhigh 
present with dispersed levels of Vβ8.2 expression and some of them express endogenous 
(non-transgenic) TCR chains at the levels equivalent to TCR expression in WT rats. Thus, 
TCRhigh T cells in rMT-II rats most likely represent those cells that during development 
have escaped allelic exclusion and express a second TCR from the endogenous promoter 
that is somewhat stronger than the promoter driving transgene expression. Because 
MBP-specific effector T cell lines established from rMT-II rats become uniformly TCRint 
(data not shown), T cells with high TCR expression seem to be less reactive to MBP and 
therefore are lost during repeated cycles of stimulation in vitro. Furthermore, when T 
cells isolated from naïve rMT-II rats are transferred into WT recipients, only the TCRint 
fraction responds to the injection of cognate antigen by proliferation (FIG 6D), indicating 
that TCRhigh  cells react poorly to MBP. Since T cells recovered from the CNS are 
predominately TCRhigh, it is unlikely that local recognition of MBP accounts for their 












FIG 6 Phenotype of rMT-II T cells in naïve animals. 
Cells from blood, cervical lymph nodes (LNs), spinal cord (SC) and intraepithelial lymphocyte (IEL) 
preparation from the gut of rMT-II rats were isolated as described in METHODS, stained and analyzed by 
FACS to analyze T cell numbers and the expression of CD62L and CD25 surface markers. 
(A) The frequency of αβTCR+ GFP+ T cells among gated living cells is representative of n > 10 samples in 
blood and LNs, n = 3 samples in the gut IELs and n = 6 samples in SC. The number of T cells infiltrating the 
SC and the SC parenchyma (SC par) is expressed as mean ± SD of n = 3 samples. 
(B) The frequency of CD62L+ and - T cells is presented as mean ± SD of n = 5 samples in blood, LNs and SC 
and of n = 3 in gut IELs. 
(C) The frequency of CD25+ T cells in blood and SC is expressed as mean ± SD of n = 3 samples. The 
histogram is representative of n = 6 experiments. 
(D) The outline of experimental approach for in vivo testing antigen response of rMT-II T cells and 
representative flow cytometry results of measuring antigen-dependent proliferation in vivo (n = 6). CTV, 
Cell Tracer Violet; OVA, ovalbumin. 
 
4.5 Intrathecal transfer of primary rMT-II T cells is not sufficient for the 
induction of clinical disease 
Very low numbers of rMT-II T cells in the CNS and the prevalence of TCRhigh fraction 
among them (presumably having no or very little MBP reactivity) may suggest that there 
are not enough self-reactive T cells entering the target organ to trigger the cascade of 
pathogenic events leading to EAE. To test this assumption, we decided to increase the 
number of T cells entering the CNS by performing an intrathecal injection of about 5 
million rMT-II T cells isolated from a pool of LNs, blood and spleen into rMT-II rats. In 
another group of rMT-II rats we injected the same number of pathogenic effector T cell 
blasts of an rMT-II T cell line, harvested two days after MBP stimulation in vitro. 
Interestingly, none of the rats injected with primary T cells developed EAE. In contrast, 
the rMT-II effector T cell blasts were able to induce a typical monophasic EAE course, 
starting on the third day after transfer, in all the injected animals (FIG 7A and B). In order 
to verify the presence of the transferred T cells in the CNS, rMT-II LNs-blood-spleen T 
cells were intrathecally injected in WT rats. As shown in FIG 7C, the transgenic green cells 
were found one day later both in the spinal cord and in the brain of these rats. Therefore, 
these results indicate that the functional state rather than the number of MBP-specific T 






FIG 7 Intrathecal injection of freshly activated effector but not primary rMT-II T cells induces EAE 
disease. 
(A,B) rMT-II rats were injected intrathecally with 5x106 rMT-II T cells. The clinical score and the percentage 
of weight variation were measured daily in each rat. 
One group of rMT-II rats (n = 3) was injected with T cells of a rMT-II T cell line (in red). Another group was 
injected with rMT-II T cells magnetically isolated from a pool of LNs, spleen and blood (transferred rats n 
= 6) of naïve rats (in green). (C) WT rats (n = 2) were injected intrathecally with 5 million rMT-II T cells 
isolated by MACS from a pool of LNs, spleen and blood of naïve rats. One day after transfer, the brain and 
the SC were extracted after perfusion, in order to quantify by FACS the GFP rMT-II T cells inside the central 
nervous system. 
All data are presented as mean ± SD. In (C) is shown the mean ± SD (n = 2) of the GFP T cells number per 
total organ. Student’s t test was performed for all statistical analyses: In (A,B) is shown the statistical 




4.6 Recently activated effector T cells show a much higher level of 
activation in the CNS than naïve or resting memory T cells 
Our hypothesis that the functional state of the T cells dictates encephalitogenicity was 
further tested in a following set of experiments. We performed transfer or active EAE 
induction in rMT-II rats and analyzed the activation status of different T-cell subsets (FIG 
8A). In the case of EAE induced by the transfer of TMBP-mCherry cells, we isolated T cells from 
the blood and inflamed CNS at the onset of disease. Under this condition we could 
distinguish three populations of T cells, namely effector T cells (Cherry+, GFP-, CD62L-), 
naïve rMT-II T cells (Cherry-, GFP+, CD62L+) and memory rMT-II (Cherry-, GFP+, CD62L-). 
In the case of active EAE induced by immunization, we also isolated T cells from the blood 
and inflamed CNS at the onset of disease. Under this condition we could distinguish two 
populations of T cells, these being effector/memory T cells (GFP+, CD62L-) and naïve rMT-
II T cells (GFP+, CD62L+) (FIG 8B).  
In the transfer EAE experiments, effector TMBP cells were found in the blood and in the SC 
tissue at disease onset. As expected, the numbers of effector TMBP cells in this early clinical 
phase predominated over those of the recruited rMT-II T cells (FIG 8B). Recruited rMT-
II T cells isolated from SC were almost exclusively CD62L negative, whereas in the blood 
about 80% were naïve (GFP+, CD62L+; FIG 8B). Similarly to transfer EAE, under condition 
of immunization nearly all rMT-II T cells entering the SC were CD62L negative (FIG 8B). 
Therefore, naïve T cells are largely not capable of entering the CNS either in healthy 
condition or in the early stage of EAE disease.   
In the transfer EAE experiment, the effector TMBP cells expressed higher levels of CD25 
than rMT-II T cells both in the blood and in the SC (FIG 8C). The upregulation of CD25 
expression in the SC relative to blood, which is indicative of antigenic stimulation, was 
stronger in effector TMBP cells than in rMT-II T cells (FIG 8C). However, in active EAE 
experiments, recently rMT-II T cells activated in the periphery also markedly upregulated 
CD25 upon entry into CNS (FIG 8D), very much like effector TMBP cells in the transfer EAE 
settings. 
Further, we analyzed gene expression in T cells sorted by flow cytometry from blood and 
SC tissue in both types of EAE. As expected, effector TMBP cells isolated from SC tissue 
strongly upregulated the expression of pro-inflammatory cytokines IFNγ, IL-17 and GM-




gene (encoding CD25 protein, detected earlier by immunostaining). In contrast, rMT-II T 
cells recovered from SC tissue in transfer EAE showed only marginal increase of IFNγ, IL-
17 and GM-CSF mRNA levels relative to levels in blood derived rMT-II T cells (FIG 9). In 
active EAE, rMT-II T cells in the SC tissue induced expression of pro-inflammatory 
cytokines much more strongly than did rMT-II T cells passively recruited in transfer EAE 









FIG 8 Transfer versus active EAE in rMT-II rats. 
(A) In the first group EAE was induced in rMT-II rats by transfer of 4x106 effector TMBP cells transduced in 
culture with retrovirus encoding mCherry red fluorescent protein (transfer EAE). The second group of rMT-
II animals was immunized with MBP in CFA (Active EAE). When animals developed clinical EAE (day 3 for 
transfer EAE and day 6 for active EAE) spinal cord tissue and blood were analyzed by flow cytometry. In 
(B) is shown the frequency of αβTCR+ GFP+ (GFP T cells) and αβTCR+ mCherry+ GFP- (effector mCherry T 
cells) T cells in blood and SC after transfer EAE (top panels) and the number of GFP T cells in both the 
compartments in active EAE (bottom panels). Histogram shows the difference in CD62L expression of GFP 
T cells in the blood (blue) and in the SC, (red) both after transfer and after active EAE induction. In the 
overlay dot plots in (C) are compared the frequencies of CD25+ cells among the effector mCherry T cells 
(red) and the rMT-II GFP T cells (green) both in the blood and in the SC, after transfer EAE induction. The 
histograms in (C) show the difference in CD25 expression between the two groups of cells in the blood and 
in the SC, after transfer EAE induction. In (D) is shown the difference in CD25 expression between the rMT-






FIG 9 Analysis of T cell activation in transfer and active EAE in TCR transgenic rMT-II rats.  
Experimental setup is outlined in FIG 8A. The rats were sacrificed around day 3 after transfer, or day 6 after 
immunization. The cells were isolated from blood and spinal cord (SC), stained for αβTCR and sorted by 
FACS as αβTCR+ GFP+ T cells (in blue for Active EAE; in green for Transfer EAE) and as αβTCR+ mCherry+ 
GFP- T cells (in red). The graphs show the expression level of IFNγ, IL-17, CD25 and GM-CSF normalized to 
β-actin gene expression. All data are presented as mean ± SEM of n = 3 for active EAE and n = 3 and 6 for 
transfer EAE. The statistical analysis was performed by student’s t test. In the graphs are shown the 




The entire population of rMT-II T cells in TCR transgenic rats is functionally heterogenic, 
i.e. it contains naïve and memory subsets and the memory subset itself may consist of 
central memory, effector memory and resident memory T cells. Moreover, the presence 
of TCRhigh population with uncertain antigenic specificity complicates the interpretation 
of our results. Therefore, we decided to perform similar experiments in CD4 TMBP 
“memory” rats, as this system allows an analysis of a more uniform population of T cells 
with well-defined antigenic specificity and differentiation history. To this end, we 
generated “memory” rats using GFP-tagged TMBP cells established in culture and 
neonatally transferred into WT Lewis recipients. These “memory” animals were used as 
a host for transfer of effector TMBP-Cherry cells to induce transfer EAE, or were subjected to 
immunization with MBP in CFA (FIG 10A). In transfer EAE settings, both recently 
activated effectors (Cherry+) and resting memory (GFP+) T cells were readily identified 
in blood at the day of onset of clinical symptoms, and both cell types entered SC tissue 
showing similar proportional enrichment (~5 fold) among all T cells detected (FIG 10B). 
The CD25 expression of the two T cell subsets was similar in the blood and evidently 
increased in the SC in both T cell groups. Instead, the OX40 expression was different in 
the blood, but only the one in recently activated effector T cells increased in the SC (FIG 
10B). Immunization of “memory” rats resulted in a prominent increase of GFP+ T cells 
frequency in the blood (from 0.7 to 5.9% of all T cells) and in the SC tissue (from 3.6 to 
58.7% of all T cells) (FIG 10C). Furthermore, ex-memory TMBP cells recently activated in 
the peripheral lymph nodes by immunization, upon entry into SC tissue upregulated 










FIG 10 Analysis of transfer and active EAE in TMBP-memory rats. 
(A) Memory rats were prepared by i.p. injection of 2x106 resting effector TMBP-GFP cells into newborn Lewis 
rats and 8 weeks later the engraftment was confirmed by flow cytometry analysis of peripheral blood 
samples. EAE was induced in the first group of “memory” rats by transfer of 4x106 TMBP-mCherry effector T cell 
blasts (transfer EAE) and in the second group by immunization with MBP in CFA (active EAE). The rats with 
clinical signs of disease were sacrificed 3 days after transfer (B) or 6 days after immunization (C). The cells 
were isolated from blood and spinal cord (SC) and analyzed by flow cytometry (B,C). (B) Shown is the 
frequency of GFP memory and mCherry effector T cells among the whole T cell population in blood and SC 
in transfer EAE. Numbers in the dot plots are frequencies of indicated T cell types (mean ± SEM of n = 5). 
(C) Shown is the frequency of GFP memory T cells in active EAE. The dot plots are representative of n = 4. 
 
Analysis of gene expression in T cells sorted from the CNS of memory rats at the onset of 
transfer or active EAE revealed substantial upregulation of IFNγ, IL-17 and CD25 
transcripts in both transferred effector TMBP-Cherry cells and ex-memory TMBP-GFP re-
activated in the periphery by immunization prior to re-entering the circulation (FIG 11). 
Interestingly, passively recruited memory TMBP-GFP cells in transfer EAE settings showed 




FIG 11 Activation of MBP-specific T cells in the target tissue during transfer and active EAE in TMBP-
memory rats. 
IFNγ, IL-17 and CD25 gene expression in the FACS-sorted T cell populations from memory rats (FIG 10 A-
C). The data are RT-qPCR results and normalized to the level of β-actin expression (mean ± SEM of n = 3 or 





Together our data obtained in two different models, TCR transgenic and memory rats, 
indicate that a memory (antigen-experienced) phenotype of T cells is prerequisite for 
them to enter CNS tissue, however the efficient re-activation of T cells in situ requires not 
only appropriate TCR specificity (MBP) but also a certain functional state characteristic 
for effector T cells that recently perceived strong antigenic stimuli outside of the CNS. 
 
4.7 Antigenic stimulation of T cells is followed by the wave of glycolytic 
activation which subsides over time 
Which functional properties distinguish resting memory and recently activated effector 
(ex-memory) T cells? One of them might be a metabolic switch, namely activation of 
glycolysis evoked by TCR-driven signaling (FIG II). To characterize the glycolytic state in 
TMBP cells cultured in vitro, we measured the uptake of glucose by flow cytometry using 
fluorescent glucose analogue 2-NBDG (FIG 12A). Exposure of TMBP cells to cognate 
antigen presented by thymic APCs resulted in a rapid increase of glucose uptake that 
peaked 2-3 days after stimulation and subsequently declined to initial low levels (FIG 
12A). Further, we compared the glycolytic rate and glycolytic capacity in blast (day 2) 
versus resting (day 6) effector TMBP cells using an extracellular acidification rate (ECAR, 
measure of lactate production) as read-out (FIG 12B). Thus, we confirmed that TCR 

















FIG 12 Glucose uptake and glycolysis rate in the effector MBP-specific T cells during their re-
stimulation cycle in vitro. 
TMBP cherry cells were stimulated in vitro with thymic APCs and MBP antigen (A,B). (A) Results of glucose 
uptake assay. At the indicated time point after stimulation T cells were collected, stained with 2-NBDG and 
analyzed by FACS. FACS dot plots show gating strategy to exclude co-cultured thymocytes and dead cells 
from the analysis. Multicolor histograms depict 2-NBDG fluorescence intensity at different time points. The 
percentage of T cells with high 2-NBDG signal and its mean fluorescence intensity (MFI) are plotted over 
time. The control group (Cnt, depicted in grey) represents the TMBP cherry cells without 2-NBDG staining. Data 
are representative of three different T cell lines and are shown as mean ± SD of n = 4. (B) Extracellular 
acidification rate (ECAR) assay performed on Seahorse system. T cells were collected on the day 2 and 7 
after stimulation. The graph shows ECAR for blast (day 2) and resting (day 7) effector T cells pre-incubated 




DG). The data are shown as mean ± SD of n = 8 (blast) and n = 6 (resting) replicates. Student’s t test was 
used for the statistical analysis.  
 
Next, we analyzed the transcriptional response upon activation in vitro. We analyzed 
genes important for the glycolysis along with classical targets of TCR-driven activation 
such as IFNγ and CD25. The expression of glycolytic enzymes, hexokinase 1 (HK-1) and 
lactate dehydrogenase A (LdhA), as well as IFNγ and CD25, reached a peak within the first 
24 hours after stimulation and then decreased (FIG 13A).  
We also analyzed mRNA expression of three positive regulators 
of glycolysis, Irf4, Hif1α and cMyc (Myc proto-oncogene, bHLH transcription factor) 
transcription factors, and of Bcl6, a transcription factor that negatively regulates 
glycolysis. Irf4 showed a monophasic increase similar to the kinetic of the LdhA gene, 
whereas Hif1α mRNA expression exhibited a bimodal response resembling the 
transcriptional kinetic of HK-1. Interestingly, the Bcl6 gene expression did not show a 
high regulation in the first 9 days in vitro but, as expected, was found to be increased in 
“memory” rats. The mRNA expression of cMyc increased soon after stimulation and then 
decreased over the 9 days in vitro but, unexpectedly, was found to be high in “memory” 
rats (FIG 13B). 
When T cells were transferred in WT rats 2 days after activation in vitro, the expression 
of all the analyzed glycolytic genes during the preclinical migratory period throughout 
the body (1 to 3 days after transfer) followed the same trend seen in the corresponding 
days in vitro (days 3, 4 and 5 after in vitro stimulation) (FIG 13A-C). Indeed, the genes 
showed a low and stationary level of expression in all the organs analyzed during the 3 
days in vivo, and finally, an increase only when the T cells entered the spinal cord (SC) 





FIG 13 Expression of glycolytic enzymes and regulatory factors in T cells over time upon activation. 
TMBP cells were stimulated in vitro with thymocytes and MBP. Two days after stimulation T cells were either 
used for transfer EAE or left in culture. RNA was isolated from cultured T cells (A,B) or from cells sorted at 
the indicated time point from different organs of animals that received transfer of TMBP-Cherry cells (C) or 
from not immunized “memory” rats (A,B; pooled LN, blood and spleen, n= 3). Expression levels of indicated 




of HK-1 and LdhA genes encoding glycolytic enzymes. Plot on the right depicts expression of HK-1 gene at 
smaller scale for better resolution. IFNγ and CD25 genes were used as a read-out confirming efficient 
activation of T cells. (B) Expression of key transcription factors known to regulate metabolism of effector 
T cells. (C) MBP–specific T cells were sorted from mediastinal lymph nodes (LN), lung (Lu), blood (Bl), 
spleen (Sp) and spinal cord (SC) tissue by flow cytometry. The graph shows levels of expression in vivo 
compared to levels in vitro for the same T cell line before adoptive transfer. All the data in the figure are 
presented as mean ± SEM. 
 
As the protein expression is a more adequate measure of pathway activity than mRNA 
expression, we also analyzed glycolytic and other metabolic enzymes over time in vitro 
(FIG 14) and in transfer EAE (FIG 15) by Western blot. This analysis also documented 
that expression of glycolytic enzymes after peaking at day 2 after antigenic stimulation 
slowly decreases both in culture and in vivo after T-cell transfer. Interestingly, the decline 
of glycolytic enzyme expression was more pronounced in the ex vivo isolated T cells 
(compared normalized values for glycolytic enzymes in FIG 14 and FIG 15). TMBP cells 
recovered from the spinal cord at the onset of EAE showed reversion of glycolytic 
enzymes to the levels observed soon after antigenic stimulation in culture (FIG 14-15). 
Thus, in situ re-activation of TMBP cells within the target tissue seems to be sufficient for 





FIG 14 Time course analysis of metabolic pathways in cultured effector TMBP cells. 
MBP–specific T cells were stimulated in vitro by addition of thymic APCs and cognate antigen. Protein 




using antibodies specific for indicated proteins. β-actin was used for normalization. (These experiments 
were performed in collaboration with group of Giuseppe Matarese at the Department of Molecular 
Medicine and Medical Biotechnology of the University of Napoli, “Federico II”). 
 
We also detected a decline of lipid synthesis, which closely followed the profile of changes 
seen for glycolysis. Furthermore, after entry of the T cells into the CNS and their local re-
activation, their lipid synthesis was resumed (FIG 14-15). Remarkably, the induction of 
mTOR signaling upon entry into the CNS was only moderate compared to levels observed 





























FIG 15 Time course analysis of metabolic pathways in transferred effector TMBP cells. 
MBP–specific T cells were sorted from mediastinal lymph nodes (LN), lung (Lu), blood (Bl), spleen (Sp) and 
spinal cord (SC) tissue by flow cytometry. Protein lysates isolated from different organs at indicated time 




for normalization. (These experiments were performed in collaboration with group of Giuseppe Matarese 
at the Department of Molecular Medicine and Medical Biotechnology of the University of Napoli, “Federico 
II”). 
 
4.8 Inhibition of glycolysis in vivo affects T-cell encephalogenicity  
As described in the previous sections, the glycolysis rate in T cells rapidly increases upon 
stimulation and then slowly decreases over time. It is possible that the glycolysis rate 
present in T cells by the moment of TCR engagement can influence their potential to 
become activated. We decided to inhibit T-cell glycolysis in vivo and analyze effect of such 
treatment on the EAE. To this end, we injected MBP-reactive GFP-labeled effector T cells 
(TMBP GFP cells) in WT rats, and treated them with daily intraperitoneal administration of 
2-Deoxy-D-glucose (2-DG) (FIG 17A). This drug targets glucose metabolism in several 
ways. First, 2-DG competitively inhibits the glucose transporters (GLUTs). Afterwards, 2-
DG is phosphorylated by hexokinase to form 2DG-6-P (2-DG-6-phosphate) that cannot be 
further metabolized via glycolysis and accumulates in the cell. In this way, 2DG-6-P 
noncompetitively inhibits HK and thus the phosphorylation of glucose to glucose-6-
phosphate (G-6-P), and competitively inhibits PGI and its action on the conversion of G-
6-P to fructose 6-phosphate (FIG 16, Zhang et al. 2014). 
 




When animals transferred with TMBP-GFP cells were treated with 2-DG during the 
preclinical period (day 0-3) or until the peak of clinical disease (day 0-6), we observed a 
delay in the EAE onset comparing to control group but the severity at the peak and 
recovery phase of disease were similar (FIG 17A). 2-DG treatment did not seem to alter 
the viability or migratory distribution of TMBP-GFP cells during preclinical period as their 
numbers detected in the blood, spleen and mediastinal LNs were not significantly 
changed (FIG 17B). Instead, we found a reduction in the number of TMBP-GFP cells 
infiltrating meninges and parenchyma of SC at day 3.5 after transfer when control and 2-
DG treated groups showed a difference in the clinical scores (FIG 17C). At this time point 
the numbers of myeloid cells (OX42+) and recruited host T cells (GFP-) infiltrating SC 
parenchyma were also reduced in the 2-DG treated group (FIG 17E). Later in the course 
of EAE at day 4.5, numbers of infiltrating immune cells were no longer significantly 
different (FIG 17D and F), which was in agreement with the elevation of clinical scores 
at this stage. In the transfer EAE induced by administration of a lower amount of TMBP 
cells, the clinical effect of glycolysis inhibition was even more evident (FIG 17G).    
Immunostaining for CD25 and OX40 surface markers indicates that in the SC meninges 
and parenchyma of rats treated with 2-DG, TMBP-GFP cells were less activated than in 
control animals (FIG 18A-C). 
Altogether these results support our hypothesis that the glycolytic state of TMBP cells 
entering CNS tissue determines their re-activation efficiency. An alternative explanation 
of how inhibition of glycolysis influences clinical EAE disease is that 2-DG treatment 
blocks induction of glycolysis caused by local re-activation of T cells inside the CNS, and 
this in turn negatively affects the effector function of the T cells. Moreover, 2-DG 
treatment in vivo may compromise functions of other cell types (not T cells) contributing 
to the induction of EAE. Therefore, we decided to analyze the relationship between 











FIG 17 Effects of 2-DG treatment on transfer EAE. 
TMBP-GFP cells (3x106) were injected intravenously in WT rats in order to induce tEAE. (A) One group of 
animals (n = 3) was daily i.p. injected with 500 mg/kg 2-DG from day 0 to day 3 after transfer (orange). 
Another group was treated in the same way from day 0 to day 6 (n = 3; red). The control group was treated 
with daily injection of PBS from day 0 to day 6 (blue). Mean ± SEM clinical scores are shown. The data are 
representative example of 4 independent experiments. Statistical significance was determined by student’s 
t test. (B-E) Analysis of TMBP cell numbers and numbers of immune cells infiltrating SC and the other 
indicated compartments at the indicated time points - day 2.5 (n = 3), 3.5 (n = 4) and 4.5 (n = 3) determined 
by flow cytometry. (G) 2-DG treatment of rats receiving lower number of encephalitogenic T cells (2x106) 









FIG 18 Effects of 2-DG treatment on the activation levels of MBP-specific effector T cells.  
Flow cytometry analysis of CD25 and OX40 expression in transferred TMBP-GFP cells in the course of transfer 
EAE described in the legend of FIG 17. Cells isolated from blood and SC tissue at the day 2.5 (A), day 3.5 (B, 
onset of clinical symptoms) and day 4.5 (C) were stained with antibodies specific for CD25, OX40 or isotype 
control IgG (grey histograms) and measured by FACS. Shown are overlay histograms representative of 3 
independent experiments. 
 
4.9 The inhibition of glycolysis in cultured T cells lowers their level of 
activation in vitro 
T cells in vitro showed the peak of glycolysis around the second day after stimulation, but 
then they retained a high rate also after 3 days (FIG 13-15). We decided to start 2-DG 
treatment 3 days after stimulation and used medium containing no glucose (FIG 20A). In 
order to compensate for essential metabolites normally produced via glycolysis, e.g. ATP, 
we used a galactose containing medium for 2-DG treatment. Galactose promotes ATP 
synthesis mainly by mitochondrial oxidation of pyruvate (Le Goffe et al. 1999; van der 
Windt et al. 2016). Recent work shows that CD4 T cells activated in galactose fuel 
proliferation and survival with ATP from oxidative phosphorylation (OXPHOS) and not 
via aerobic glycolysis and that these cells could also use glutamine as an alternative 
substrate for OXPHOS (Chang et al. 2013). 2-DG could interfere only partially with the 
glycolysis and oxidation of galactose (Le Goffe et al. 1999) because, in this case, the 
formation of glucose-6-P follows a different pathway and makes use of different enzymes 
compared with what is happening in the glucose catabolism (FIG 19). Therefore, we 
reasoned that combination of galactose with 2-DG in glucose-free medium would inhibit 
glycolysis without compromising the viability of T cells. 
 




After the continued galactose/2-DG treatment for 4 days (FIG 20A), T cells were re-
stimulated under regular conditions (glucose containing medium without 2-DG). Their 
cytokine production was then analyzed by qPCR and ELISA. This analysis revealed a 
reduction in IFNγ, IL-17 and IL-2 mRNA expression in the treated T cells (gala + 2-DG) 
versus control (glucose) T cells, for both low (1 µg/ml) and high (8 µg/ml) concentration 
of antigen (FIG 20B). At the protein level, the production of IFNγ cytokine by 2-DG pre-
treated T cells was found to be slightly reduced relative to control T cells but this 
difference did not reach statistical significance (FIG 20C). Inhibition of glycolysis had a 
much stronger effect on the secretion of the IL-2 cytokine, especially at the lower dose of 
MBP used for stimulation (FIG 20C). Intracellular staining of re-stimulated T cells for 
IFNγ showed a reduced amount of this cytokine per cell basis in the 2-DG treated group 
when a high concentration of MBP was used for stimulation (FIG 20D). Finally, adoptive 
transfer of TMBP cells which prior to re-stimulation in vitro experienced inhibition of 







FIG 20 Effects of 2-DG treatment on the activation of effector T cells in vitro. 
(A) Outline of experimental approach to test the role of glycolysis in vitro. TMBP GFP cells were stimulated 




continued to be cultured in the glucose-sufficient medium (glucose, blue) and the other half was cultured 
in a glucose-free medium, supplemented with galactose and 5 mM 2-DG (gala + 2-DG, red). On day 7 after 
stimulation, both the control and the treated cells were re-stimulated in glucose-containing medium, with 
thymocytes and three different MBP concentrations (0, 1 or 8 µg/ml). During the next two days after re-
stimulation (d1 a.r., d2 a.r.), the T cells and their supernatant were collected at several time points (0, 12, 
18, 24, 36 and 48 h), in order to analyze their gene expression by RT-qPCR (B), and cytokine production by 
ELISA (C). On day 2 after re-stimulation some TMBP GFP cells from both groups were collected and stained 
for intracellular IFNγ (D). (B) Time course of IFNγ, IL-17 and IL-2 gene expression determined by RT-qPCR 
(normalized to the levels of β-actin gene expression). MBP concentrations used for the second stimulation 
are indicated. Data are mean ± SEM of n = 2 replicates of two different experiments. (C) ELISA 
measurements of IFNγ and IL-2 concentration in supernatants of two groups at the indicated time points 
after re-stimulation with MBP. Data are mean ± SEM of n = 3 replicates. The histograms in (D) show results 
of intracellular IFNγ staining in control and treated TMBP GFP cells. Samples were stained 48 h after re-
stimulation with 1 or 8 µg/ml MBP. The histograms are representative of n = 3 replicates. (E) Clinical course 
of EAE induced by transfer of TMBP cells that were cultured in the indicated media before the last re-
stimulation in vitro (n = 3 animals per group). All the statistical analyses in the figure were performed by 
student’s t test. 
 
These results show that decreased glycolysis rate prior to re-stimulation in vitro does not 
completely abolish T cell activation but it does reduce the level of their activation. 
 
4.10 The glucose uptake and expression of glycolytic enzymes in T cells 
before entry into the CNS is higher in recently activated effector T cells 
than in resting memory or naïve T cells 
We performed a transfer experiment in rMT-II rats (FIG 21A) in order to compare the 
state of glycolysis between effector TMBP cells and circulating memory and naïve rMT-II T 
cells immediately before they enter SC tissue. In the blood-derived effector TMBP cells we 
found higher expression of HK-1 and LdhA genes and similar levels of Eno 1 mRNA 
transcript comparing to memory or naïve rMT-II T cells (FIG 21B). The levels of Irf4 and 
Hif1α expression did not differ significantly between effector TMBP and memory rMT-II T 
cells found in the blood (FIG 21B). Blood-derived naïve rMT-II T cells showed a slightly 
lower expression level of Hif1α gene (FIG 21B). The transition of effector TMBP cells from 
blood to the SC tissue was associated with a moderate increase in glycolytic enzyme 




agreement with our results described earlier in this manuscript. Remarkably, memory 
rMT-II cells isolated from SC tissue also exhibited a higher expression of all five tested 
genes relative to the levels detected in blood memory rMT-II T cells (FIG 21B).  
Further, we measured glucose uptake by effector TMBP and rMT-II T cells isolated from 
blood at the onset of EAE. Indeed, we found that effector TMBP cells accumulate more 2-
NBDG substrate than rMT-II T cells (FIG 21C,D). Together these results indicate that right 





FIG 21 State of glycolysis in different subsets of MBP-specific T cells analyzed during transfer EAE 




FIG 21 State of glycolysis in different subsets of MBP-specific T cells analyzed during transfer EAE 
in rMT-II rats. 
(A) EAE was induced in rMT-II rats by transfer of 4x106 effector TMBP-Cherry cells. (A) The rats were sacrificed 
at the onset of clinical disease. Cells were isolated from blood and spinal cord (SC), stained for αβTCR and 
CD62L and sorted by flow cytometry into three groups: naïve (αβTCR+ GFP+ CD62L+; blue), resting 
memory (αβTCR+ GFP+ CD62L-; green) and effector T cells (αβTCR+ mCherry+ GFP-; red) (B) . Expression 
of HK1, LdhA, Eno 1, Irf4 and Hif1α genes was determined by RT-qPCR and normalized to β-actin gene 
expression (mean ± SEM of n = 4 for bloods and n = 3 for SC). (C,D) The cells were isolated from the blood 
of n = 6 animals, stained for αβTCR, with or without 2-NBDG and analyzed by FACS. Gating strategy (C) and 
green fluorescence (FL-1) of 2-NBDG and GFP (D, overlay contour plot) are shown. The columns in (D) 
represent the difference in green fluorescence intensity between cells stained and not stained with 2-NBDG 
in each T cell population. Data are presented as mean ± SD (n = 6). Statistical analyses performed by 




















The aim of this study was to get an insight into the mechanisms by which autoreactive T 
cells can maintain their tolerance to self CNS tissue. Myelin antigen specific T cells are 
frequently found in healthy subjects (Bielekova et al. 2004; Tejada-Simon et al. 2001), 
and only rarely, when unknown factors compromise self-tolerance, do these T cells 
acquire pathogenic capacity and induce an autoimmune attack of the CNS leading to 
disease such as MS. Our initial observation made in MBP-TCR transgenic and in TMBP-
memory Lewis rats was a lack of spontaneous disease and aggravation in transfer EAE. 
This observation convinced us that these two models would be suitable for addressing 
mechanisms that help to keep autoreactive T cells in check.  
First we could show that T cells isolated from rMT-II animals are not anergic, induce upon 
activation in the periphery early-onset disease and are able to transfer disease 
susceptibility to an EAE resistant host (FIG 2-3). Nevertheless, we found that primary 
rMT-II T cells isolated from naïve animals respond to the antigen in vitro much more 
weakly and more slowly than effector T cells of the same genetic background. It is 
however possible that the type of APCs utilized for the in vitro stimulation, namely 
thymocytes, is inefficient in activating primary T cells. 
Our analysis of non-inflamed CNS tissue from naïve rMT-II animals revealed that a very 
low number of T cells are present there. Those T cells found had a memory and not a 
naïve phenotype. When we artificially increased the number of T cells by intrathecal 
transfer of primary rMT-II T cells, comprising naïve and memory subsets, this 
manipulation failed to induce clinical disease. In contrast the intrathecal administration 
of effector T cells induced classical monophasic EAE as did i.v. transfer (FIG 7). From this 
we conclude that the entry of MBP-specific rMT-II T cells into CNS per se is not sufficient 
for the initiation of pathogenic processes but that in addition a certain functional state of 
T cells is needed in order for them to become re-activated and to launch an inflammatory 
reaction. Seemingly, such a state characteristic for effector T cells is missing (or 
insufficient) in primary rMT-II T cells but could be induced in these cells by immunization.      
To determine whether highly pathogenic effector T cells differ from naïve and resting 
memory rMT-II T cells in their capacity to become activated in the target organ, we 




we observed that the entry of naïve T cells into an inflamed CNS is barely detectable. 
Importantly, the levels of activation inside the CNS were similar for effector T cells in 
transfer EAE settings and for recently activated ex-memory T cells in active EAE settings. 
In contrast, the activation level of memory rMT-II T cells recruited to the CNS during 
transfer EAE were significantly lower than the activation of co-infiltrating transferred 
effector T cells. This might well explain why the clinical course of transfer EAE in rMT-II 
rats is indistinguishable from the one in WT Lewis rats. MBP-specific memory rMT-II T 
cells, although present in high numbers inside SC, are not efficiently activated in situ and 
thus do not contribute significantly to the inflammatory process.         
We corroborated our findings obtained from EAE experiments in rMT-II animals using an 
alternative model, TMBP-“memory” rats which enable the analysis of a well-defined 
memory T cell population of the same antigenic specificity and developmental history as 
an effector TMBP cell population. In fact, our data indicate that resting memory TMBP 
entering CNS during transfer EAE are less activated than effector TMBP cells, whereas 
recent antigenic stimulation in the periphery restores the potential for the re-activation 
in ex-memory TMBP cells to the levels seen in transferred effector T cells.  
Effector and memory T cell subsets drastically differ in their usage of several metabolic 
pathways. One of these pathways, glycolysis, is induced by TCR-driven signaling (Ho et al. 
2015) and itself can regulate effector function of T cells (Chang et al. 2013). We could 
confirm that effector T cells rapidly upregulate glycolysis after antigenic stimulation. This 
upregulation was transient and coincided with induction of mRNA of genes encoding 
transcription factors cMyc, Irf4 and Hif1α known to positively regulate the expression of 
glycolytic enzymes. After a period of high glycolytic activity, both in vitro cultured T cells 
and T cells transferred to a recipient animal for EAE induction, showed a gradual decline 
in glycolysis (FIG 13-15). Interestingly, TMBP cells re-activated inside the CNS resume 
their glycolytic activity (FIG 15). Whether this is required for effector function of 
encephalitogenic T cells remains unclear.    
Pharmacologic inhibition of glycolysis during the preclinical phase of transfer EAE 
delayed the disease onset but could not block disease development (FIG 17). Therefore, 
a high glycolytic rate may be a factor contributing to but not solely determining the 
potential of effector T cells to become re-activated in the CNS. Furthermore, the results of 
our in vivo 2-DG administration supports the idea that the modulation of metabolic 




targets glycolysis in different types of cells other than T cells, e.g. myeloid immune cells 
and resident cells in the CNS. Consequently, the clinical effect of 2-DG may not be 
explicitly linked to T cell activation. Nevertheless, the reduced number of CNS-infiltrating 
TMBP cells and recruited myeloid cells along with the lower expression of T cell activation 
markers in animals treated with 2-DG suggest that a lowered glycolysis rate inhibits the 
activation of TMBP cells. It cannot be ruled out that 2-DG treatment also affects the 
induction of glycolysis in situ after re-activation of T cells in the CNS.  
To pinpoint how glycolysis inhibition impacts on T cell activation we performed an in 
vitro analysis and showed that 2-DG treatment of T cells prior to stimulation reduces 
production of effector cytokines such as IFNγ and IL-2. This argues in favor of our 
hypothesis that the glycolytic state modulates the re-activation potential of T cells. It also 
suggests that an impediment on re-activation of T cells might be the main mechanism of 
the 2-DG effect on transfer EAE.       
The results shown in FIG 21 finally demonstrate that during transfer EAE the glycolysis 
rate of T cells migrating through the blood to the CNS is higher in recently activated T 
cells than in resting memory or naïve T cells. Together with the evidence pertaining to 
the different degrees of activation of these T cell subsets in the SC, the results suggest that 
the glycolysis rate present in T cells just before they enter the CNS and come into contact 
with local APC-antigen complexes can play a role in influencing their activation level. 
Moreover, it is also interesting that rMT-II and recently activated T cells show a similar 
glycolytic gene expression in the SC, except for Irf4 and, to a minor extent, for HK-1. This 
leads us to hypothesize that once stimulated, rMT-II T cells switch on their activation 
machinery as well as the recently activated T cells, but somehow, probably involving Irf4 
and related to their previous glycolysis level, keep their inflammatory state low to the 
point of being undetectably pathogenic in the CNS. 
In conclusion, even if we are still not aware of the mechanism behind the role of the 
glycolysis level in regulating T-cell activation, our findings open up possibilities for 
treatments aimed at modulating the immune potential of T cells by targeting the level of 
glycolysis before activation. This could be useful in reducing the pathogenicity of auto-
reactive T cells and at least mitigate the clinical course of autoimmune diseases such as 
multiple sclerosis. Moreover, it could be possible to enhance the immune capability of 
exhausted or hyporesponsive T cells such as the tumor-infiltrating lymphocytes, kept in 




environmental deprivation of oxygen and nutrients (Schietinger and Greenberg 2014; Ho 
et al. 2015). Therefore, such treatment could help to break the unresponsiveness of 
tumor-specific T cells and thus, be valuable in treating cancers. 
 
6. SUMMARY AND CONCLUSIONS 
With this study we have demonstrated that endogenous naïve and memory MBP-reactive 
T cells are not pathogenic in Lewis rats and that only recently activated effector T cells 
are able to induce EAE, suggesting that the functional state of the cells can determine the 
disease development. Indeed, we have shown that, after EAE induction, a T cell’s level of 
activation in the CNS strikingly depends upon its functional state, and whereas effector T 
cells become highly activated, memory cells show just a low degree of activation. 
We examined the dynamics of glycolysis over time in T cells upon antigenic stimulation 
in vitro, and we also studied these dynamics in vivo, and have shown that the glycolysis 
rate reaches its peak soon after antigen encounter and then gradually decreases over time. 
In fact, after transfer EAE induction, memory T cells exhibit a lower level of glycolysis 
compared to recently activated effector T cells when analyzed in the blood on the last day 
of their peripheral migratory pathway to the CNS. 
These findings suggest that the rate of glycolysis prior to stimulation can influence the 
level of activation of MBP-reactive T cells in the CNS. To corroborate this hypothesis, we 
demonstrated that the inhibition of glycolysis in MBP-reactive T cells could lower their 
level of activation and pathogenicity upon stimulation, even under optimal conditions. 
Even though the exact mechanisms behind this phenomenon have yet to be elucidated, 
our results point to the possibility of influencing the immune potential of T cells by 
modulating their level of glycolysis. This could prove useful in the treatment of 
autoimmune diseases such as multiple sclerosis, or even of cancer, the latter being a 
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8. LIST OF ABBREVIATIONS 
2-DG:   2-deoxy-D-glucose. 
2DG-6-P: 2-Deoxyglucose-6-phosphate. 
2-NBDG:  2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose. 
Ab:   Antibody. 
ACAT2: Acetyl-CoA C-acetyltransferase 2. 
ACK:   Ammonium chloride potassium. 
aEAE:   Active EAE. 
Ag:   Antigen. 
AKT1:  AKT serine/threonine kinase 1. 
AMPK:  AMP-activated protein kinase. 
APC:   Antigen presenting cell. 
Apo-A4: Apolipoprotein A-IV. 
AQP4:  Aquaporin-4. 
ATP:   Adenosine triphosphate. 
BBB:   Blood-brain barrier. 
Bcl6:   B cell lymphoma 6. 
Bl:   Blood. 
BLIMP1:  B lymphocyte-induced maturation protein-1.  
BSA:   Bovine serum albumin. 
CCR7:   C-C motif chemokine receptor 7. 
CD:   Cluster of differentiation. 
CD25:  Interleukin 2 receptor alpha. 
CD62L:  L-selectin. 
cDNA:  Complementary deoxyribonucleic acid. 
CFA:   Complete Freund’s adjuvant. 
cMyc:  Myc proto-oncogene, bHLH transcription factor. 
CNS:   Central nervous system. 
CRAC:  Ca2+ release-activated Ca2+ channels. 
CSF:   Cerebrospinal fluid.  
CXCR3:  C-X-C motif chemokine receptor 3. 
CXCR4:  C-X-C motif chemokine receptor type 4. 
DLAT:  Dihydrolipoamide S-Acetyltransferase. 
DMEM:  Dulbecco’s modified Eagle’s medium. 
DMSO: Dimethyl sulfoxide. 
DNA:   Deoxyribonucleic acid. 
EAE:   Experimental autoimmune encephalomyelitis. 
ECAR:  Extracellular acidification rate. 
EDTA:  Ethylenediaminetetraacetic acid. 




ELISA:  Enzyme-like immunosorbent assay. 
Eno 1:  Enolase 1. 
EOMES:  Eomesodermin. 
ER:   Endoplasmic reticulum. 
ETC:   Electron transport chain. 
FACS:   Fluorescence-activated cell sorting.  
FADH2:  Flavin adenine dinucleotide. 
FAO:   Fatty acid oxidation. 
FAsyn:  Fatty acid synthase. 
FAS:   Fatty acid synthesis. 
FCS:   Fetal calf serum. 
FSC:  Forward scatter.   
G-6-P:  Glucose-6-phosphate. 
Gala + 2DG:  Galactose + 2 Deoxy-D-glucose. 
GAPDH:  Glyceraldehyde-3-phosphate dehydrogenase. 
GFP:   Green fluorescent protein. 
GLUT:  Glucose transporter. 
GM-CSF:   Granulocyte-macrophage colony-stimulating factor. 
GPE:   GP+E86 packaging cell. 
Hif1α:  Hypoxia-inducible factor 1α. 
HK-1:   Hexokinase 1. 
HLA:   Human leucocyte antigen. 
i.p.:  Intraperitoneal. 
i.t.:  Intrathecal. 
i.v.:  Intravenous. 
IEL:   Intraepithelial lymphocytes. 
IFNγ:   Interferon gamma. 
IL15:   Interleukin 15. 
IL-17:   Interleukin 17. 
IL-2:   Interleukin 2.  
IL7:   Interleukin 7. 
IP3:   Inositol 1,4,5-trisphosphate.  
Irf4:   interferon-regulatory factor 4. 
LdhA:   Lactate dehydrogenase A. 
LFA-1:  Lymphocyte function-associated antigen 1. 
LN:   Lymph node. 
LSM 1077:  Lymphocyte separation medium. 
Lu:   Lung. 
MACS:  Magnetic-activated cell sorting. 
MAG:   Myelin-associated glycoprotein. 
MBP:   Myelin basic protein. 
Med LN:  Mediastinal lymph node. 




MFI:  Mean fluorescence intensity. 
MOG:   Myelin oligodendrocyte glycoprotein. 
mRNA: Messenger ribonucleic acid. 
MS:   Multiple sclerosis. 
mTOR: Mammalian target of rapamycin. 
mTORC1:  Mammalian target of rapamycin complex 1. 
Myc:   MYC proto-oncogene, bHLH transcription factor. 
NAD+:  Nicotinamide adenine dinucleotide (oxidized form). 
NADH:  Nicotinamide adenine dinucleotide (reduced form). 
NFAT:  Nuclear factor of activated T cells.  
NF-M:   Neurofilament. 
NMO:   Neuromyelitis optica. 
OVA:   Chicken egg ovalbumin. 
OX40:  Tumor necrosis factor receptor superfamily, member 4. Also cluster of 
differentiation 134 (CD134). 
OXPHOS:  Oxidative phosphorylation. 
PAMP:  Pathogen-associated molecular pattern. 
PBS:   Phosphate buffered saline. 
PCR:  Polymerase chain reaction. 
PEP:   Phosphoenolpyruvate. 
PGI:   Phosphoglucose isomerase. 
PI3K:   Phosphoinositide 3-kinase. 
PKM1/2:  Pyruvate kinase isozymes M1/M2. 
PLP:   Proteolipid protein. 
pPCR:  Quantitative polymerase chain reaction. Also, real-time polymerase chain 
reaction. 
PP-MS:  Primary progressive multiple sclerosis. 
PPP:   Pentose phosphate pathway. 
PRR:   pattern recognition receptor. 
pS6:  Phospho-S6 ribosomal protein. 
qPCR:  Quantitative (or real time) PCR. 
RM:   Restimulation medium. 
rMT-II:  Rat MBP-specific T cell receptor MHC class II-restricted. 
RNA:   Ribonucleic acid. 
rOT-II:  Rat OVA-specific TCR transgenic MHC class II restricted. 
RR-MS:  Relapsing-remitting multiple sclerosis. 
RT-qPCR: Quantitative reverse transcription polymerase chain reaction. 
s.c.:   Subcutaneous. 
S-100β:  S100 calcium binding protein B. 
S1P1:   Sphingosine-1-phosphate receptor 1.  
S6:  S6 ribosomal protein. 
SC par:  Spinal cord parenchyma. 




SDHA:  Succinate dehydrogenase complex flavoprotein subunit. 
SERCA:  Sarco/endoplasmic reticulum Ca2+-ATPase. 
SOCE:   Store-operated Ca2+ entry. 
Sp:   Spleen. 
SP-MS:  Secondary progressive multiple sclerosis. 
SRC:   Spare respiratory capacity. 
SSC:   Side scatter. 
STIM:   Stromal interaction molecule. 
TCA:   Tricarboxylic acid. 
TCGF:   T cell growth factor. 
Tcm:   Central memory T cells. 
TCM:   T cell medium. 
TCR:   T cell receptor. 
Tem:   Effector memory T cells. 
tEAE:  Transfer EAE. 
Th1:   T-helper 1. 
Th17:   T-helper 17. 
TLR:   Toll-like receptors. 
TNFα:  Tumor necrosis factor alpha. 
VLA-4:  Very late antigen 4. 
WT:   Wild-type. 
α-KG:   α-ketoglutarate. 
αβTCR: T cell receptor alpha and beta chains. 
 
